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Effects of Long-Term Administration of Caffeine in a 
Mouse Model for Alzheimer’s Disease 
William Schleif 
 
ABSTRACT 
 A recent epidemiological study suggested that higher caffeine intake reduces the 
risk of Alzheimer’s disease (AD).  Caffeine, a widely consumed stimulatory drug, is a 
non-selective adenosine receptor antagonist that has been shown to increase plasma 
adenosine levels in rodents. To determine any long-term protective effects of caffeine in a 
controlled longitudinal study, caffeine was added to the drinking water of APPsw 
transgenic (Tg) mice between 4 and 9½ months of age, with behavioral testing done 
during the last 6 weeks of treatment.  The average daily intake of caffeine per mouse (1.5 
mg) was the human equivalent of 5 cups of coffee/day.  Across multiple cognitive tasks 
of spatial learning/reference memory, working memory, and recognition/identification, 
Tg mice given caffeine (Tg+Caff) performed significantly better than Tg control mice 
and similar to non-transgenic controls.  Discriminant Function Analysis involving 
multiple cognitive measures clearly showed the superior overall cognitive performance of 
Tg+Caff mice compared to Tg controls.  Analysis of Aβ in the hippocampus by ELISA 
revealed Tg+Caff mice had significantly less soluble Aβ1-40 and insoluble Aβ1-42. In a 
follow-up study involving neurochemical analysis only, caffeine was added to the 
drinking water of 17 month old APPsw mice for 18 days.  In this study, Tg+Caff mice also 
 vii
showed a significant reduction of insoluble Aβ1-42 in the hippocampus. In contrast to the 
reduced extracellular brain levels of adenosine in Tg controls, caffeine treatment 
normalized brain adenosine levels in Tg mice to that of non-transgenic controls. Analysis 
of amyloidogenic secretase activity revealed the reduction in Αβ is likely because of a 
reduction in γ−secretase activity as a result of increased SAM silencing of PS1 
expression. This study suggest that a modest, long-term caffeine intake of approximately 
500 mg per day (5 cups of coffee) may reduce considerably the risk of AD by decreasing 
amyloidogenesis. 
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I. Alzheimer’s Disease 
 With exponential growth in the population of aged individuals in industrialized 
countries comes the increasing prevalence of age-related disorders. Foremost amongst 
these disorders is Alzheimer’s disease (AD), which is currently the leading cause for 
dementia in the elderly and afflicts an estimated 4.5 million people in the United States 
alone. This number is expected to triple over the next fifty years if a cure is not found 
(Hebert et al., 2003). The onset of Alzheimer’s is as tragic as it is devastating; 
progressively disrupting areas of the brain responsible for memory and motor skills that 
ultimately leave the patient comatose and unable to communicate or relate with their 
environment before they succumb to death. This continual decline of the patient’s 
lifestyle leaves them in a state that is a strain on their family and is costly to society. 
Behavior Characterization 
 The initial onset of AD is often times difficult to pinpoint. During the latent 
period of the disease, the underlying disruptions in normal brain physiology begin to 
occur decades before any cognitive decline is noticed. Some patients develop a condition 
termed MCI (Mild Cognitive Impairment), which is characterized by the progressive 
decline of short-term memory and indicates a substantial risk for developing AD. An 
estimated 10-15% of MCI patients progress into AD per year, yet it is also worth 
mentioning that not all MCI subjects develop AD (Petersen et al., 2001). MCI represents 
a transitional state where patients have a noticeable decline in memory different from that 
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of normal aging but are not yet diagnosable as having AD. The short-term memory 
impairment found in MCI is similar to AAMI (Age-Associated Memory Impairment), but 
cognitive testing can distinguish between the two. Some MCI patients exhibit 
neuropsychiatric symptoms as well. A recent case study found over 30% of MCI patients 
exhibited symptoms of depression, aggression, anxiety, apathy and irritability. These 
symptoms follow a similar trend seen in early AD patients and may serve as a clinical 
indicator of MCI severity (Feldman et al., 2004). 
 Early AD is marked by a moderate loss in working memory that is frequently 
accompanied by depression and the symptoms mentioned earlier. Typically language 
difficulties also appear with the patient struggling with tests that involve word-finding 
and recall. Patients progress into moderate AD when the severity of these symptoms 
increase. In addition to a significant decrease in short term memory, the language 
difficulties seen in early AD worsen. Moderate AD patients often times create spatially 
disordered writing and rely on simpler grammatical sentences to express themselves 
(Forbes et al., 2004). Long term memory loss also develops, and moderate AD patients 
are prone to wandering and hallucinations as well. The progressive and debilitating 
decline in cognition eventually leads to the nearly absolute loss of intellect in the 
advanced stage of AD preceding death. The advanced stage of AD also sees the initial 
deterioration of motor and sensory skills. Patients in this stage live in a vegetative, 
bedridden state, unable to care for themselves in any function. 
Pathological Characterization 
 The prominent lesions characteristic of AD brain pathology, neuritic plaques and 
neurofibrillary tangles, were first described by Alois Alzheimer in 1906 but the exact 
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chemical compositions of these lesions were only discovered in the past four decades. 
The extracellular neuritic plaques, primarily found in the cerebral cortex and 
hippocampus, are composed mainly of amyloid β−peptide (Aβ), a protein that 
accumulates in various degrees during normal aging. Several genetic mutations affect the 
onset of AD by increasing the rate of Aβ production, through mechanisms that will be 
discussed later. Neurofibrillary tangles consist of intracellular paired helical filaments 
that are left behind as “tombstones” when neurons degenerate. 
 Aberrant processing of the amyloid precursor protein (APP) leads to the two 
forms of Aβ found in neuritic plaques that differ in their amino acid lengths. Aβ42, the 
principal component of the core in neuritic plaques, is more susceptible to aggregation 
than the slightly smaller form of Aβ40 (Selkoe, 2001). Recognized as a potential 
precursor to neuritic plaques, diffuse plaques are composed solely of Aβ42 and generally 
lack any signs of dystrophic neurons. These diffuse plaques are found in significant 
numbers in the typical areas associated with AD but also appear in brain areas that will 
never develop mature neuritic plaques. Diffuse plaques are also found in the brains of 
healthy patients that never show any signs of dementia. Aggregation of Aβ40 with Aβ42 
leads to the more compact, fibrillar neuritic plaques associated with AD. 
 The accumulation of fibril Aβ in the extracelluar space activates microglia within 
and surrounding neuritic plaques, which attempt to clear Aβ by phagocytosis and release 
free radicals and the cytokines IL-1β and TNF-α (Schubert et al., 2000). Astrocytes are 
found in a concentric ring around the cores of mature plaques, and are activated by the 
proinflammatory cytokines released by microglia. Astrocytes expedite the rate of amyloid 
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deposition and plaque formation by releasing the inflammatory proteins α1- 
antichymotrypsin (ACT) and apolipoprotein ε  (APOE) (Potter et al., 2001). Dystrophic 
neurites are also found amid mature amyloid deposits, likely as a result of the free 
radicals and inflammatory mediators released by microglia and astrocytes. This 
neuroinflammatory cascade that results from the accumulation of Aβ forms the central 
tenant of the amyloid hypothesis as the causative agent for the cognitive decline seen in 
AD. 
 Neurofibrillary tangles (NFT) accrue when the microtubule-associated protein tau 
is phosphorylated by intracellular kinase(s). The hyperphosphorylation of tau causes it to 
uncouple from microtubules and form intracellular paired helical filaments (PHF) that 
constitute the molecular makeup of NFTs. The subsequent formation of neurofibrillary 
tangles from PHFs disrupts normal cell trafficking and may lead to neuronal death. 
Neurofibrillary tangles in AD are typically found in limbic and association cortices of the 
brain, often times in association with mature amyloid plaques (Selkoe, 2001). Although 
NFTs are considered a pathological hallmark of AD, they are also associated with several 
other neurodegenerative diseases and occasionally a late-stage AD patient may exhibit 
low levels of these tangles upon autopsy. 
 Also associated with the insidious nature of AD is a significant decline in 
synapses between neurons, as well as the atrophy of neuronal populations in the cerebral 
cortex and hippocampus. Axonal transport is crucial for synapse viability and 
accumulation of β−amyloid has been shown to inhibit fast axonal transport in cultured rat 
neurons (Hiruma et al., 2003), giving a plausible explanation for the significant loss of 
synapses seen in AD. Exposure of human cortical neurons to β−amyloid in vitro also 
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disrupts calcium regulation, leading to an increase in intracellular calcium stores that may 
enhance neuronal loss via glutamate-induced excitotoxicity (Mattson et al., 1992). This 
combined loss of synapses and neurons leads to a progressive loss of neurotransmitter 
systems that are responsible for both short and long term memory, reflecting the 
behavioral symptoms seen in AD. 
Genetics of Alzheimer’s Disease 
 The two types of Alzheimer’s disease, sporadic and familial, differ only in the age 
of onset and share similar pathological and behavioral hallmarks. The sporadic form of 
AD typically has an age of onset over 65 years and represents the majority (>95%) of 
confirmed Alzheimer’s patients. Usually the sporadic, or late-onset, form of AD has an 
unidentifiable cause aside from the possible presence of various risk factors. Patients with 
a genetic disposition to develop AD represent the familial form and constitute only a 
small percentage of all AD cases. These patients may be diagnosed with AD as early as 
their thirties, and no later than their sixties, depending on the nature of the mutation. 
Familial AD, or FAD, is linked to autosomal-dominant mutations in three causative genes 
of interest. Each of these mutations disrupts the normal processing of APP, resulting in 
increased production of β−amyloid species. 
 The APP gene is located on chromosome 21, and was initially linked to AD due 
to the similar neuropathology between AD and the genetic disorder trisomy 21, where the 
extra copy of APP leads to its increased expression and deposition of Aβ (Hardy and 
Selkoe, 2002). APP is a transmembrane protein with a long extracellular N-terminus and 
a much shorter cytoplasmic C-terminus. During normal APP processing, the protease 
α−secretase cleaves APP in the middle of the Aβ domain generating non-amyloidogenic 
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APP fragments. The less common proteolytic cleavage of APP by β− and γ−secretases 
generates the β−amyloid species found in diffuse and neuritic plaques (Zekanowski et al., 
2004). The FAD mutations linked to the APP gene change APP processing so 
that β− and γ−secretases are more likely to cleave APP and produce amyloidogenic 
fragments, thus accelerating the onset of the disease.  
 Specific mutations in the APP gene were only discovered in the past decade. A 
double missense mutation in the 670 and 671 amino acids of APP was isolated from 
several Swedish families that exhibited early onset of AD. This double point mutation 
directly favors the cleavage of APP by β−secretase and increases levels of Aβ40 and Aβ42 
(Mullan et al., 1992). Additional missense mutations in the APP gene have also been 
identified from families of other nationalities that increase the likelihood of  γ−secretase 
cleavage. In particular, a mutation at amino acid 717 of APP was found in a London 
family. This mutation increases the cleavage of APP by  γ−secretase and raises the levels 
of Aβ42, the β−amyloid species that is especially prone to aggregate. 
  Mutations in the APP gene are relatively rare however, and subsequent genetic 
screening of early onset AD patients found that the majority of FAD cases can be linked 
to missense mutations in a presenilin gene, PS1. Rarer FAD cases are seen with 
mutations in another presenilin PS2. Located on chromosomes 14 and 1 respectively, 
missense mutations in these genes have been linked to FAD cases in hundreds of families 
worldwide. The exact molecular actions of the presenilin genes have been difficult to 
ascertain, but it is widely accepted that they influence the γ−secretase cleavage site on 
APP. It is therefore not surprising that mutations in the presenilins linked to FAD 
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increase  γ−secretase activity, leading to elevated levels of Aβ42 (Tandon and Fraser, 
2002). Patients with presenilin mutations linked to FAD exhibit a 1.5 -to 3-fold increase 
in neuritic plaques compared to late-onset AD cases (Selkoe, 2001). In addition to being 
the most common cause of FAD, mutations in the PS1 gene also lead to the earliest age 
of onset and most aggressive form of the disease. 
Diagnosis of Alzheimer’s Disease 
 The importance of diagnosing AD at its earliest stage is critical because of its 
implications in the efficacy of the limited pharmaceuticals and treatments currently used 
to treat AD. Diagnosing any form of Alzheimer’s disease with complete certainty is 
nearly impossible however until the patient dies and an autopsy can be performed to 
identify the pathological hallmarks of AD discussed earlier. There are difficulties in 
recognizing the initial manifestations of Alzheimer’s symptoms and differentiating 
between the cognitive decline associated with aging and other diseases that cause 
dementia. Often times the initial diagnosis of AD is made only after other forms of 
dementia are eliminated and at this point diagnosis is probable at best. Recent work has 
failed to yield a test battery that can distinguish definitively between the cognitive decline 
of normal aging, other forms of dementia, and the initial clinical manifestations of early 
Alzheimer’s disease but many recent advances have increased the accuracy in diagnosing 
AD in more advanced cases. 
 Clinical diagnosis of AD is dependent on several criteria: gradual onset of 
dementia in the absence of other potential dementia-causing disorders between 40 -90 
years of age, impaired daily activities, behavioral alterations, family history, 
neuroimaging, and several biological markers. Some patients have relatively intact daily 
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functioning with cognitive deficits without full-blown dementia. These people fall into 
the broader categories of MCI, cognitive impairment no dementia, questionable 
dementia, isolated memory impairment and minimal AD (Nestor et al., 2004). 
  Dementia is diagnosed after a poor score on the Mini-Mental State Examination 
(MMSE), a test given during a clinical evaluation that can reveal a decline in memory. 
Other cognitive deficits seen in word naming and calculations are also seen after further 
screening. Tests are conducted to rule out common potential causes of dementia such as a 
vitamin deficiency, hyperthyroidism, neurosyphilis, or stroke before a diagnosis of 
probable AD is made. Additional support for an AD diagnosis may come from a positive 
family history, especially if AD is present in first-degree relatives. DNA diagnostic 
testing can confirm a familial basis of the disease and is useful for screening the risk of 
family members who are asymptomatic. Commercial tests are readily available for the 
more common causative mutations in the presenilin genes and for variations in the APOE 
gene that may increase susceptibility for sporadic AD, yet a clinical test for APP remains 
undeveloped. The presence of one or two copies of the ApoE4 allele with accompanying 
dementia also lends support for a more definitive AD diagnosis, as this particular allele 
confers an increased risk to developing the disease by reasons that will be discussed later 
(Gaskell et al., 2004). 
 Genetic confirmation of AD using clinical DNA testing is accurate, yet it is 
limited in its application by the relatively small number of AD cases that have a familial 
basis. Therefore, the development of biological markers that can contribute to the early 
diagnosis of sporadic AD is underway but has yet to reach widespread clinical 
application. Currently the most widely used markers for AD are amyloid-β proteins and 
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both tau and hyperphosphorylated tau protein levels collected from the CSF, but there are 
drawbacks to using either marker. AD patients are characterized by low levels of Aβ42 in 
both blood plasma and the CSF, but there is significant variability in Aβ42 levels between 
individuals. Low levels of Aβ42 may also be found in other diseases, such as depression. 
This makes it difficult to set the standard range for clinical AD in the overall population 
using this marker, yet longitudinal studies on individuals are useful (Sobow et al., 2004). 
The mechanism responsible for a decrease in Aβ42 concentrations is still open to debate. 
A recent study found a correlation between lowered CSF Aβ42 levels and the decreased 
brain volumes and enlarged ventricles found in AD patients (Wahlund and Blennow, 
2003), indicating a possible dilution effect and/or decreased production of Aβ42. It is 
more likely that the brain acts as a sink and increased deposition of Αβ42 into plaques 
reduces the concentration of Aβ42 remaining to diffuse into the blood. 
 The use of phosphorylated-tau protein (p-tau) in the CSF as a diagnostic marker 
for AD has proven to be far more accurate than Aβ42. P-tau is consistently seen in high 
levels in the CSF of AD patients, and is far more specific than Aβ42 or total tau levels for 
differentiating AD from other relevant diseases that may cause dementia. It is also useful 
for differentiating between geriatric depression and AD, even when there is significant 
overlap of clinical symptoms (Buerger et al., 2003). Unfortunately, the sampling 
technique used to collect CSF is highly invasive and this limits the application of 
both Αβ42 and p-tau as CSF biomarkers in some circumstances. When applicable and in 
conjunction with a thorough neurological evaluation and imaging techniques, the use of 
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these biological markers is very powerful in increasing the accuracy of AD diagnosis 
however. 
 Some of the more powerful diagnostic markers for AD involve imaging the 
medial temporal lobe and monitoring any alterations in particular brain areas. Repeated 
MRI studies reveal significant atrophy in this region, specifically in the volumes of the 
hippocampus and entorhinal cortex, in early to late stage AD patients (Jack et al., 1997, 
Xu et al., 2000). MRI has also been found important in identifying the early conversion 
of MCI patients to mild AD patients (DeToledo-Morrell et al., 2004), a potentially 
instrumental finding in diagnosing early AD patients at a period where current and future 
treatments can exert their most dramatic effects. 
 An additional tool in the arsenal of AD diagnostics is PET imaging. PET scans 
traditionally utilize functional imaging to detect changes in brain metabolism by using a 
radioactively labeled isotope that reveals areas of glucose metabolism. This type of PET 
scan unfortunately is only useful in detecting changes in the medial temporal lobe in 
more advanced AD cases (Ishii et al., 1998), yet this type of imaging is useful in studying 
physiological aspects of AD. Recently a radioactive ligand was developed that binds to 
Aβ plaques and allows imaging of areas of the brain with large numbers of neuritic 
plaques (Klunk et al., 2004). This new technique opens the door for easier evaluation of 
anti-amyloid therapies and as another tool in increasing the accuracy of AD diagnosis. 
Currently, radioligands for PET imaging of NFT’s remain to be developed yet research 
into this area is underway (Mathis et al., 2004). 
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Risk Factors for Alzheimer’s Disease 
 The initial onset and later progression of AD is moderated by the presence or 
absence of various risk factors. The most profound and unavoidable risk factor for AD is 
aging, yet not all of the elderly will develop AD. Another important risk factor for both 
late-onset and familial AD is inheritable, the ApoE4 allele (mentioned earlier as a marker 
used in genetic screening). The ApoE4 allele has a gene dose affect: with two copies of 
the allele conferring greater risk than possession of one copy of ApoE4 (Veurink et al., 
2003). Inheritance of this allele enhances susceptibility for sporadic AD and also 
decreases the age of onset of the disease. ApoE is involved in cholesterol transport and 
cholesterol is linked to amyloid deposition and deposition. Therefore, the propensity for 
AD due to possession of ApoE4 is believed to be as a result in a deficiency in amyloid 
clearance and subsequent increased deposition of beta-amyloid in plaques (Selkoe, 2001). 
It is also not surprising that high blood cholesterol (LDL) is also a risk factor for AD. 
 The neuronal cell losses characteristically seen in AD patients are typically 
associated with markers for oxidative stress caused by the body’s inflammatory response 
to neuritic plaques and NFTs. A diet poor in antioxidants, such as Vitamin E or others 
found in vegetables and fruit, lowers the body’s ability to respond and protect itself from 
oxidative stress. Low dietary uptake of antioxidants exacerbates neuronal oxidative 
damage and increases the risk for developing AD (Polidori, 2004). High blood levels of 
homocysteine are also associated with an increased risk of AD, but it may be as a result 
of a folic acid deficiency (Quadri et al., 2004). 
 Unlike the associated risks for AD mentioned thus far, an environmentally 
enriched lifestyle provides protection against AD and decreases the risk of developing 
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dementia with increasing age (Fratiglioni et al., 2004). Such an environment includes 
exposure to intellectually stimulating activities, as well as profound social and physical 
activities that are usually absent from most nursing homes. The cognitive benefit from 
these activities are believed to share the same pathway and all seem to reduce stress, 
increase both cognitive reserve and blood flow to the brain (Fratiglioni et al., 2004). 
Treatments for AD 
 Current treatments for AD are based on treating the symptoms rather than the 
disease itself. The commonly prescribed acetylcholinesterase inhibitors (donepezil, 
rivastigmine, and reminyl) have some efficacy in slowing down the inevitable onset of 
neuropsychiatric symptoms in patients with mild to moderate AD (Holmes et al., 2004). 
These drugs compensate for the decline in memory due to the deficits in the acetylcholine 
neuronal network in the medial temporal lobe. They increase synaptic concentrations of 
acetylcholine by blocking the enzyme acetylcholinesterase, which is responsible for 
breaking down the neurotransmitter acetylcholine. This increases the efficiency of 
remaining cholinergic neurons that have yet to be disrupted from AD progression. As AD 
advances these drugs no longer have an affect in preserving memory however. The 
acetylcholinesterase inhibitors have a relatively short window of effectiveness, typically 
between 1-2 years. 
 The only other FDA approved drug for treating AD symptoms, Memantine, was 
only recently approved for treating moderate to severe AD patients. Memantine is a non-
specific NMDA receptor antagonist that reduces glutamingeric-caused excitoxicity that 
may be present in the pathogenesis of AD. Used in conjunction with donepezil, 
memantine has been shown to make significant improvements in cognitive function and 
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daily activities in even severe AD patients (Tariot et al., 2004), but like the 
acetylcholinesterase inhibitors memantine has a relatively limited duration of 
effectiveness. 
 
 
 
II. Animal Models of AD 
 The complex etiology of Alzheimer’s disease requires a practical model that 
closely resembles the ontogeny of the disease and can provide insight into possible 
therapeutic preventions. Human testing is generally out of the question due to moral 
implications in testing novel treatments, so researchers turned to animal models. In 
particular, the mouse lines PDAPP, APPsw, and APP/PS1 have been genetically altered to 
replicate behavioral and pathological aspects of AD. These mice are manipulated by 
randomly inserting a wild-type or mutant AD transgene into the genome of a fertilized 
mouse egg. Utilizing a strong promoter that overexpresses the gene in brain-specific 
areas, these transgenic mice enable the impact of the gene of interest to be evaluated. The 
short life span of mice (1 to 2 years), while beneficial for research, requires that the 
promoter overexpress the transgene of interest so the same symptoms that may take 
decades to occur in humans will develop in mice (Seabrook and Rosahl, 1999). 
Numerous mouse lines have been developed, each with their own assets and drawbacks 
in replicating the disease in humans. 
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PDAPP Model 
Pathology.    The PDAPP mouse model incorporates a platelet-derived growth 
factor (PDGF)-β promoter in neurons in the brain to drive overexpression of a human 
APP minigene associated with the London type mutation (APP717V? F) found in some 
familial AD cases. When compared to wild type littermates, this genomic alteration 
results in a well characterized, age-dependent neuropathology exhibiting extracellular 
levels of Αβ and amyloid deposits similar to that found in AD. Diffuse and mature Aβ 
deposits are seen in the hippocampus, corpus callosum, and cingulate cortex as early as 3-
4 months old in PDAPP mice (Dodart et al., 2000). Plaque density increases with age in 
these regions and by 6-10 months numerous plaques are seen (Games et al., 1995; 
Irizarry et al., 1997). In aged PDAPP mice, increasing plaque burden is associated with 
the neuritic dystrophy, cytoskeletal alterations, synaptic degeneration, and gliosis that are 
also found in AD patients (Schenk et al., 1997; Larson et al., 1999). PDAPP mice do not 
exhibit any neurofibrillary tangles (Masliah et al., 1996) and do not develop the 
characteristic neuronal loss associated with AD however. These mice do show marked 
hippocampal atrophy by 3 months but this is possibly due to developmental 
abnormalities, independent of increased Aβ deposition (Dodart et al., 2000). 
Behavior.    Important correlations have been made between the pathological 
consequences of progressively overexpressing this mutant hAPP gene in PDAPP mice 
and the behavioral results that ensue. These mice can be behaviorally tested at various 
time points to link cognitive deficits to disruptions in specific brain areas due to 
increasing amyloid plaque burden. Initial testing found PDAPP mice develop an age-
dependent decline in object recognition that the authors linked to the increased levels of 
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Aβ plaques in cortical structures in mice older than 6 months (Dodart et al., 1999). The 
same study found deficits in spatial memory in 3, 6, and 9-10 month old PDAPP mice 
using an 8-arm radial maze. Deficits in spatial memory at the early 3 month time point 
suggest an age independent decline because this is well before significant amyloid 
deposition has occurred. In a later paper, the authors attributed this decline in spatial 
memory to the overexpression of human APP and subsequent abnormal hippocampal 
formation during development rather than increased amyloid deposition (Dodart et al., 
2000). A different study using a novel water maze task revealed an age-related decline in 
working spatial memory. These PDAPP mice were found cognitively intact at 6-9 
months, but were impaired at 13-15 months and progressively worsened by 18-21 months 
(Chen et al., 2000). These authors found this age-dependent decline did correlate with 
increased β-amyloid plaques and linked it to interruption of synaptic transmission by β-
amyloid burden. 
 Further support for an age-related decline in spatial memory in the PDAPP mouse 
line came from a recent study in 2004. This study utilized a PDAPP mouse model that 
does not exhibit abnormal hippocampal atrophy during development. Using a full 6 week 
battery that examines sensorimotor skills and cognition, Nilsson et al. (2004) found no 
differences between 2 month old PDAPP mice and the non-transgenic controls. Another 
group of PDAPP mice were tested at 16 months of age and these animals were impaired 
in Morris water maze and in overall radial arm water maze performance (RAWM) 
(Nilsson et al., 2004). Further statistical analysis of 15-16 month old PDAPP mice found 
a significant correlation between deficits in Morris water maze, platform recognition, and 
RAWM performance with the deposition of Aβ in the hippocampus and cerebral cortex 
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(Leighty et al., 2004). Such correlations provide evidence that the PDAPP mouse line 
develops impaired working memory because of accruing levels of Aβ. 
APPsw and APP23 Models 
Pathology.    The APPsw and APP23 mouse models for AD both incorporate a 
human APP gene with the ‘Swedish’ double mutation (K670N/M671L). These mutations 
enhance cleavage of APP by β- secretase which favors Aβ42 production.  These APPsw 
and APP23 models differ however because each one utilizes a different promoter that 
overexpresses APP by varying degrees. This difference leads to important distinctions 
between the two models in both pathology and behavior. 
 Initially described by Hsaio et al. (1996), the APPsw mouse line uses a hamster 
prion protein promoter limited to neurons in that brain that drives five to sixfold higher 
expression of a human APP695 insert when compared to expression of the endogenous 
mouse APP gene. The consequences of overexpressing this insert leads to abnormal 
changes in the pathology of these mice. Given the nature of the mutations in the insert, it 
is not surprising that APPsw mice show increasing levels of total Aβ in the brain. 
Specifically, Hsiao et al. (1996) found that the concentration of Aβ40 was 5-times higher 
and the concentration of Aβ42 was 14-times higher when comparing APPsw mice between 
2-8 months and 11-13 months of age. Rare plaques of insoluble Aβ begin appearing in 
small quantities as early as 6-7 months in the hippocampus and entorhinal cortex, with 
diffuse and compact plaques increasing to significant numbers by 12 months of age in the 
hippocampus and cortex of the brain (Hsiao et al., 1996; Kawarabayashi et al., 2001) 
eventually resembling similar levels found in AD patients. 
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Importantly, amyloid plaques in the CA1 area of the hippocampus of 16-month 
old APPsw mice were found in association with gliosis and neuritic dystrophy (Irizarry et 
al., 1997). Other studies have also found activated microglia in response to amyloid 
plaques in aged APPsw mice (Frautschy et al., 1998; Benzing et al., 1999). Another study 
found an accumulation of prostaglandin E2 (PGE2) and tumor necrosis factor α (TNFα), 
both mediators of inflammation from gliosis, in APPsw mice older than 10 months of age 
(Quadros et al., 2003). A further study using 21-25 month old APPsw identified areas of 
oxidative damage in association with amyloid plaques, likely because of the release of 
free radicals during the inflammatory process (Pappolla et al., 1998). The presence of 
these inflammatory proteins and Aβ-induced oxidative damage makes this mouse line an 
attractive model for testing therapeutics that target the inflammatory cascade seen in AD. 
Although the APPsw mouse line replicates several aspects of AD, namely 
amyloidosis, vascular angiopathy, free radical formation, and inflammatory mediators in 
association with amyloid plaques, it is an incomplete model of AD because these mice 
fail to develop neurofibrillary tangles and no global neuronal or synaptic losses have been 
reported. Even in aged APPsw mice, where extensive plaque formation is associated with 
inflammatory mediators and pro-oxidant activity, neuronal populations remain relatively 
consistent with neuronal numbers in non-transgenic controls in areas of the brain such as 
the hippocampus, where large numbers of neurons atrophy during the progression of AD 
in humans (Irizarry et al., 1997). With no clear abnormalities in the brain structures 
associated with learning and memory in these mice, some researchers have suggested that 
the increasing soluble levels of Aβ are to blame for the increasing behavioral 
impairments that APPsw mice exhibit as they grow older. In fact, one study found severe 
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impairment in in vitro and in vivo long-term potentiation (LTP) in neurons of APPsw 
mouse hippocampus that correlate with cognitive impairment and rising levels of both 
soluble and insoluble Aβ (Chapman et al., 1999). 
 The other mouse model that incorporates the ‘Swedish’ double mutation, the 
APP23 transgenic mouse, employs a murine Thy-1 promoter element to overexpress a 
mutant APP751 gene in neurons in the brain. These mice have a seven fold higher 
expression of the mutant APP insert than normal mouse APP (Dodart et al., 2002). 
APP23 mice develop Aβ plaques in the cortex at 6 months, much sooner than APPsw 
mice (Sturchler-Pierrat et al., 1997). Aβ plaque numbers increase with age and spread 
extensively in this model to the neocortex, hippocampus, white matter, and thalamus. 
Associated with these plaques are dystrophic neurons, activated microglial and 
astrocytes. These mice also develop congophilic angiopathy, where large deposits of 
Aβ40 are found in conjunction with the brain vasculature (Calhoun et al., 1999), a trait 
found in some 90% of AD patients (Vinters, 1987). In striking dissimilarity to the APPsw 
mouse model, APP23 mice exhibit a 14% loss of CA1 pyramidal neurons in the 
hippocampus in 14-18 month old mice, although no losses are seen in the neocortex 
(Calhoun et al., 1998). The authors attribute this loss directly to the formation of dense 
Aβ plaques. This model also fails to develop neurofibrillary tangles. 
APPsw Behavior.   An important component of the behavioral characterization of 
transgenic mice is an assessment of any sensory or motor deficits that may influence the 
performance of the mice in cognitive-based tasks. Accordingly, the APPsw mouse failed 
to show any deficits in a visible platform tasks at either 6 or 9 months of age, indicating 
that visual acuity is not impaired in these mice (Holcomb et al., 1999). Further 
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sensorimotor evaluation, assessed through the use of various agility tasks and a Preyer 
reflex test, also failed to detect any significant disturbances (Holcomb et al., 1999; 
Holcomb et al., 1998). In a later study, APPsw mice at 3, 9, 14, and 19 months of age 
were subjected to a full battery of sensorimotor tasks. The authors concluded that 
younger APPsw mice are not impaired in motor function overall, and older transgenic 
mice show impairment similar to non-transgenic controls (King et al., 2002). Recently, 
Arendash et al., (2004) reported that 6 month old APPsw are impaired in a balance beam 
task, but perform normally in the elevated maze task for anxiety and other sensorimotor 
tasks, such as string agility. Additionally, Leighty et al. (2004) found no correlation 
between the balance beam task, a measure of sensorimotor skills, and cognitive 
performance. The lack of any sensory or motor abnormalities in APPsw mice, or 
significant correlation with cognitive performance, validates linking any performance 
issues in cognitive-based tasks to disruptions in memory, not to the physical attributes of 
the mice. 
 The Y-maze alternation task has elucidated deficits in mnemonic processing in 
the APPsw mouse, but inconsistently so. Hsiao et al. (1996) first found 3 month old APPsw 
mice performed similar to controls, yet 9 month old Tg+ mice showed significant 
impairment in spontaneous alternation in this task. King et al. (2002) found APPsw mice 
aged 3, 9, 14, and 19 months had an “overall” reduced alternation in the Y-maze task 
when all age groups were analyzed collectively. In a later study, Arendash et al. (2004) 
found APPsw mice were impaired overall in spontaneous alternations at 5 and 8.5 month 
time points collectively. On the other hand, Holcomb et al. (1999) reported APPsw mice 
were impaired in alternation behavior at 3 months yet were unimpaired at 9 months of 
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age. This task is likely not as sensitive as some of the other cognitive-based tasks because 
Y-maze impairment remains inconsistent in this mouse model, although differences in 
methodologies and genetic backgrounds may play a role in these discrepancies.  
 Not surprisingly, 15-17 month old APPsw mice also showed significant T-maze 
alternation impairment (Chapman et al., 1999). The authors correlated the poorer T-maze 
impairment to their in vivo findings of impaired long-term potentiation in both the CA1 
and dentate gyrus regions of the hippocampus from the same mice and suggest that rising 
Aβ levels in these aged mice acts directly to infer synaptic deficiencies evident in 
reduced LTP. Unfortunately at this late age, the authors could not discriminate between 
the effects of soluble or insoluble Aβ, although the authors hint diffusible forms of Aβ 
are most likely responsible. This group also showed the APPsw mouse model lacks 
deficits in sensorimotor attributes, but only used an open field task to claim this. 
 Initial cognitive testing of APPsw mice using the Morris water maze revealed no 
differences in learning and memory in spatial reference tasks between non-transgenic and 
transgenic mice at 3 months of age (Hsiao et al., 1996). At a later age in this study 
however, 9 month old APPsw were found impaired in their escape latency in the same 
task and also spent less time in the platform’s quadrant in the probe trial, indicating these 
mice did not learn the location of the platform. Recently in 2004, however, Arendash et 
al. found impaired acquisition and retention performance in the Morris water maze as 
early as 5.5 months of age, suggesting the initial appearance of small Aβ oligomers are 
responsible for impairment of both reference learning and memory. A previous study 
done by King and Arendash (2002) reported their mice were unimpaired in Morris water 
maze even up to 19 months of age. These contrasting results from the same lab were 
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suggested to be caused by the different background strains of the mice used in these 
studies or by changes in their genetic backgrounds caused by multiple generations of 
inbreeding. These differences enabled the effects of the transgene to become more 
evident in the later study. Further evidence for the role of cognitive disturbances by small 
Aβ oligomers came from a study that reported impaired reference memory in the Morris 
water maze task at 6 months of age in APPsw mice (Westerman et al., 2002). Although 
one study using the Morris water maze failed to replicate cognitive impairment in 6 or 9 
month old APPsw mice, this is likely because of differences in testing paradigms and the 
genetic backgrounds that exist between mouse colonies in different labs (Holcomb et al., 
1999). In summary, the consensus of the behavioral studies thus far indicate Morris water 
maze impairment in APPsw mice begins around 6 months of age. 
Using a circular platform task adopted from rat behavioral studies, King et al. 
(2002) found 3, 9, 14, and 19 month old APPsw mice perform comparably to non-
transgenic age-matched controls, with both groups showing a learning effect that reduced 
the number of errors made over the 7 day testing period. Arendash et al. (2004) reported 
no differences between 6 month old APPsw mice and non-transgenics in circular platform 
performance as well. Testing by Pompl et al. (1999) revealed impairment in 7 month old 
APPsw mice during a reversal learning phase of the circular platform task however. APPsw 
mice learned the location of the escape hole in relation to various cues as well as non-
transgenic mice; however, when the escape hole was moved, transgenic mice showed 
increased errors and escape latency that failed to improve. This is a different variation of 
the task however, and the literature is consistent in reporting a lack of impairment of 
APPsw mice in the standard circular platform task at any age. 
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 Additionally, APPsw mice repeatedly show poor performance in other cognitive 
tasks. Hsiao et al. (1996) reported impaired platform recognition latency in 9-10 month 
old APPsw mice that coincided with increases in soluble Aβ. King et al. (2002) also 
showed APPsw mice at 9 months of age were significantly slower in locating a visible 
platform, and both of theses studies performed the platform recognition task after 
conducting the Morris water maze task. Recently, a similar behavior paradigm using the 
platform recognition task identified impairment even earlier in 6 month old APPsw mice 
(Arendash et al., 2004). In contrast, Westerman et al. (2002) found unimpaired platform 
recognition performance throughout the 2 year life span of the mice, but this test was 
performed before Morris water maze testing. Impaired escape latency for APPsw mice in 
the platform recognition task thus has been suggested to reflect difficulties in switching 
between the spatial (cued) strategy used in Morris water maze to a search/recognition 
strategy that ignores the previously learned extra-maze spatial cues. This explains why 
APPsw mice are impaired in the platform recognition task after they have already learned 
the platform location in the Morris water maze task, but have not been impaired in the 
platform recognition task if it is done prior (Arendash et al., 2004, Westerman et al., 
2002). 
 The radial arm water maze (RAWM) is a sensitive working-memory task used to 
evaluate both short term memory and delayed memory recall. The first testing of APPsw 
mice in the RAWM task found 15.5 month old mice made significantly more errors in the 
trial 5 component of the task when compared to non-transgenic controls, indicating these 
mice were deficient in working memory (Morgan et al., 2000). RAWM testing of 
younger 6.5-7 month old APPsw mice revealed that these animals made more errors 
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overall in both the trial 4 and trial 5 components of the task, further highlighting the 
deficits these mice have in working memory (Arendash et al., 2004). The consistent 
working memory impairment these mice show in this task by 6.5 months of age indicates 
the oligomeric form of Aβ is likely responsible for their cognitive impairment, as these 
young mice have yet to develop amyloid plaques. 
 In summary, APPsw mice do not develop any gross sensorimotor deficits that 
would otherwise impair performance in cognitive tasks. These mice consistently develop 
significant impairment in reference learning/memory that is apparent in the Morris water 
maze as early as 5.5-6.5 months and is likely caused by the increasing amounts of soluble 
Aβ oligomers. The difficulties in switching escape strategies are also apparent for 9 
month or older APPsw mice in the platform recognition task, which is reflected in their 
increased escape latencies. APPsw mice also exhibit working memory impairment in the 
RAWM task at 6.5 months of age, as these mice make more errors in the trial 4 and 5 
components of the task. Based on these overall behavioral findings, it is reasonable to 
expect 8-9 month old APPsw mice will have impaired reference learning/memory, 
impaired recognition/identification, and impaired working memory evident in the tasks 
discussed thus far. 
 The APP23 mouse model has undergone behavioral characterization as well. A 
behavioral characterization of the APP23 model was done by Kelly et al. (2003) at 3, 18, 
and 25 months of age using passive avoidance tasks, platform recognition, and small and 
large Morris water maze tasks. Age-related impairments in passive avoidance and in 
small pool acquisition were reported, while APP23 mice were found to be impaired at 
every time point in the larger Morris water maze during acquisition testing. The authors 
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also reported visual deficiencies were not responsible for this impaired spatial learning by 
using a platform recognition task in the larger pool. An age-related decline in Morris 
water maze and probe trial performance was reported also at the early age of 3 and 6 
months, while 2 month old animals were unimpaired when compared to non-transgenic 
controls (Van Dam et al., 2003). Further studies have also reported progressive deficits in 
acquisition (learning) of the Morris water maze task in both 16 month (Lalonde et al., 
2002) and 2 year old APP23 mice (Dumont et al., 2004). In addition, increased 
exploratory behavior was detected in 2 year old APP23 mice through the use of the open 
field task, while anxiety was decreased in the open arm (+) maze task (Dumont et al., 
2004). The repetitive results of impaired spatial memory in APP23 mice in the Morris 
water maze indicates these animals represent an effective model for behavioral testing in 
AD, yet the behavior of these mice in working memory tasks, such as the RAWM, that 
examine long term memory remains to be determined. 
PSAPP Model 
Pathology.    The PSAPP, or APPsw/PS-1, mouse model is a combination of two 
mutations associated with familial Alzheimer’s disease. The same “Swedish” mutation 
used in APPsw mice that enhances β-secretase activity on APP and a PS-1 mutation that 
favors the enzymatic cleavage of APP by γ-secretase are both overexpressed in this 
model resulting in an exponential increase in Aβ levels with aging, even when compared 
to that of transgenic APPsw mice (Holcomb et al., 1998). Studies have shown that PSAPP 
mice begin showing Aβ deposits in both the hippocampus and cortex between 3-6 
months of age (Takeuchi et al., 2000), with significant numbers present by 9-12 months 
of age (Borchelt et al., 1997; Holcomb et al., 1998). Although deposits of Aβ resemble 
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those found in AD, compact plaques of fibrillar Aβ have been reported to form before 
diffuse plaques in the PSAPP model, whereas this trend is opposite in human AD 
(Gordon et al., 2002). Nevertheless, by 12 months of age the compact plaques in PSAPP 
mice are surrounded by dystrophic neurites, reactive microglia and GFAP-expressing 
astrocytes, indicating that a neuroinflammatory response is present (Gordon et al., 2002). 
In depth analysis of the inflammatory response in PSAPP mice found that amyloid 
plaques increase continuously with age up the latest age studied, 25 months (Matsuoka et 
al., 2001). These authors found cyclooxygenase-2 (an inflammatory response protein) in 
conjunction with the astrocytes surrounding amyloid plaques. Complement component 1q 
was identified with the microglia associated with amyloid plaques, which indicates 
microglia may be attempting to clear amyloid via the complement pathway. 
Like the other AD animal models discussed thus far, the PSAPP mouse line also 
fails to develop neurofibrillary tangles. Takeuchi et al. (2000) reported a non-significant 
loss in cortical and CA1 neurons of the hippocampus in 12 month old PSAPP mice, yet 
this study used a low sampling number. A further study of 22 month old PSAPP found a 
38.5% reduction in CA1 pyramidal neurons (Sadowski et al., 2004). Deficits in LTP have 
also been found as early as 3 months in PSAPP mice, when amyloid plaques and deficits 
in short term memory first appear (Trinchese et al., 2004). 
PSAPP Behavior.    The first study to examine behavioral aspects of PSAPP mice 
found that by 3-4 months these mice had significantly impaired alternation performance 
in the Y-maze task, months before the initial deposition of Aβ has been detected 
(Holcomb et al., 1998). The same lab found that this deficit in Y-maze performance 
persisted with increasing age, as PSAPP mice were also impaired at 6 and 9 months of 
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age (Holcomb et al., 1999). This same study also failed to detect any deficits in spatial 
working memory at 6 or 9 months of age using the Morris water maze. These results 
show that behavioral deficits are likely due to the presence of soluble Αβ. Using a full 
behavioral battery, a later study found that PSAPP mice showed no change in 
spontaneous Y-maze alternations at either 5-7 or 15-17 months of age (Arendash et al., 
2001). This same study also showed normal Morris water maze performance at 5-7 
months of age but an aged-related impairment in this task was found later at 15-17 
months. Another study investigating the effects of a lifelong immunization with human 
Aβ found unvaccinated PSAPP mice were impaired in both Morris water maze and the 
radial arm water maze (RAWM) at 4-6 months and 15-16 months of age (Jensen et al., 
2005). Similar impairments in RAWM at 15.5 months were reported in another study of 
PSAPP mice (Morgan et al., 2000). The findings of cognitive impairment at such an early 
age in this same colony of mice was attributed by the authors to multiple generations of 
crossbreeding that enhances the susceptibility of the mice to the effects of mutant APP 
overexpression. 
Early PSAPP working-memory deficits at 3-4 months of age in the RAWM and 
impaired reference-memory in the Morris water maze at 6-8 months were also reported 
by Trinchese et al. (2004). The working-memory impairment was evident in the number 
of errors the PSAPP mice made in the RAWM that strongly correlated with Aβ levels 
and amyloid burden in these mice. A further correlation was made between RAWM 
errors and synaptic deficiencies in LTP at 6-8 months of age. The authors propose this 
lends additional support to the idea that increasing Aβ levels and amyloid burden impair 
LTP, thus reducing the animals’ performance in tasks based on cognition. 
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Limits of Animal Models for Alzheimer’s disease 
 In addition to the various pathological aspects of AD that fail to materialize in AD 
transgenic mice (such as neurofibrillary tangles or global neuronal loss that were 
mentioned earlier for each specific model) are differences in mouse and human pathology 
that possibly may skew the generalizations made after a potential therapeutic is tested. 
Specifically, Aβ plaques in both APP23 (Kuo et al., 2001) and APPsw mice (Kalback et 
al., 2002) were found to be soluble in SDS-containing buffers whereas human Αβ 
plaques are not, indicating mouse plaques are less dense. This distinction is important 
because it is believed to be responsible for the weaker complement response to Αβ 
plaques and the resultant weaker inflammatory cascade found in APP23 mice (Schwab et 
al., 2004). Knowing that human fibrillar Aβ plaques are neurotoxic from in vitro studies 
(Lorenzo et al., 2000), a less compact form of these plaques in the mice may also explain 
the lack of neuronal losses in animal models of AD. 
 Transgenic mice are also incomplete in their behavioral replication of the disease. 
Many of the behavioral aspects of early Alzheimer’s disease are difficult to ascertain in 
humans even through the use of cognitive tests such as the MMSE that examine various 
aspects of memory. Semantic memory, such as word or event recall, is usually the first 
apparition signaling Alzheimer’s disease in humans and cannot be assessed in a mouse 
animal model. Obviously the language difficulties which surface in moderate AD are also 
problematic to examine in mice. Mouse animal models are thus limited to behavioral 
measures that examine spatial learning/memory, recognition/identification, exploratory 
behavior, sensorimotor skills, and anxiety, which may only give some insight into the 
onset of depression, motor skills, or memory impairment of this disease in mice. 
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 Given these limits in replicating all aspects of Alzheimer’s disease, transgenic 
mice still have been paramount in our understanding of the disease and the possibility of 
developing therapeutics that lay the foundation for future clinical testing looks promising 
through the use of these mice. 
 
 
 
III. Caffeine Consumption and Alzheimer’s Disease 
 There is little doubt that the widespread consumption of caffeine by the global 
population makes it an important consideration when evaluating dietary influences on the 
etiology of human diseases. Caffeine can be found in popular foods and beverages such 
as tea, coffee, cocoa, chocolate, and soft drinks that constitute dietary items consumed 
sometimes as a chronic staple of the Western diet. The average caffeine consumption in 
the US is equivalent to 1-2 cups of coffee a day, or 168 mg/person/day (Fredholm et al., 
1999). Caffeine may also be found in certain aspirins and other over-the-counter drugs, 
although these would not represent a source of long-term caffeine ingestion. 
 Caffeine’s stimulatory effects on behavior and attention have been known for 
some time, but its effects on other aspects of human neurobiology have only recently 
begun to be explored. Epidemiological studies indicate that sufficient daily caffeine 
intake throughout life may be neuroprotective in both Parkinson’s disease (Ross et al., 
2000) and Alzheimer’s disease (Maia and Mendonca, 2002). Notably, Maia and 
Mendonca found that AD patients consumed markedly less caffeine (74 mg/day) during 
the twenty years preceding diagnosis of AD when compared to age-matched controls 
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(199 mg/day). Daily caffeine intake included any potential sources of caffeine and was 
not solely restricted to caffeine ingested from coffee. This information suggests that 
chronic caffeine intake during the middle years of life may delay or even prevent 
altogether the onset of the behavioral symptoms seen in sporadic Alzheimer’s disease, an 
important finding. 
 The molecular mechanism(s) that grants caffeine’s neuroprotective effects 
remains to be clearly elucidated, but many possibilities have been suggested. Once this 
mechanism has been identified, caffeine-based therapeutics could become useful in 
treating neurodegenerative diseases because of their availability and general lack of long-
term side effects. 
Pharmacological Profile of Caffeine 
 Whether taken orally or administered intravenously, the pharmacokinetics of 
caffeine are identical in humans and animals (Arnaud, 1993). Likewise, the 
gastrointestinal absorption and bioavailability of caffeine reaches 99-100% within 45 
minutes of ingestion in both human and animal models (Bonati et al., 1984, Blanchard 
and Sawers, 1983a). Peak plasma level of caffeine is reached between 15 and 120 
minutes after ingestion in humans, with a half-life that ranges from 2.5 to 4.5 hours in 
humans (Arnaud, 1987) and only 0.7 to 1.2 hours in rats and mice (Bonati et al., 1984). It 
is also known that the plasma half-life of caffeine remains relatively unchanged in both 
young adults and the elderly (Blanchard and Sawers, 1983b). On average, a typical cup of 
coffee provides a caffeine dose of 0.4 to 2.5 mg/kg which gives a peak plasma 
concentration of caffeine of 1 to 10 µM (Fredholm et al., 1999). This information, once 
accounting for weight and metabolic differences between animal models and humans, 
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allows for interpolations for dose-dependent effects between caffeine studies in animal 
models and humans. 
 Caffeine’s hydrophobic nature allows for rapid absorption through all biological 
membranes, hence its rapid absorption into the bloodstream. This same tendency also 
allows caffeine to freely pass through the blood brain barrier (Tanaka et al., 1984), an 
obstacle that limits the design and size of many other potential neurotherapeutics. Once 
absorbed into the blood stream, caffeine is also broken into its main derivatives by the 
liver. Caffeine’s major metabolites in rodents and humans with bioactivity include 1,3-
dimethylxanthine (theophylline) and 1,7-dimethylxanthine (paraxanthine). Both of these 
compounds were found to mimic some of caffeine’s effects in the CNS and which will be 
discussed in greater detail later on (Benowitz et al., 1995). Theophylline in particular is 
of interest because of its common use as a treatment for asthma and other diseases that 
increase bronchial constriction. 
Molecular Actions of Caffeine 
 Caffeine has been used experimentally for some time to study its inhibitory effect 
on cyclic nucleotide phosphodiesterase isozymes of the brain and other tissues of the 
body (Vernikos-Danellis and Harris, 1968). The caffeine dose needed in order to achieve 
this effect, however, is within the millimolar range which far exceeds typical human 
plasma levels of caffeine after ingestion. This same range is also required to release 
intracellular calcium stores via activation of ryanodine receptors (McPherson et al., 
1991). In addition, caffeine plasma levels in excess of 500 µM, or more than 50 cups of 
coffee, are toxic, likely because of caffeine’s blockade of GABAA receptors at this 
extreme range (Fredholm et al., 1999). Therefore, it is reasonable to assume that neither 
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of these actions of caffeine can be attributed to its neuroprotective effects that are being 
investigated. The only other molecular action of caffeine that can be achieved within 
physiological doses in the CNS is adenosine receptor antagonism, a mechanism that is 
shared by both theophylline and paraxanthine. In fact, theophylline’s affinity for 
adenosine receptor antagonism is three to five times higher than caffeine (Fredholm et al., 
1999). Theophylline has also been shown to enhance hippocampal LTP, yet the dose 
needed for this effect is in the 100 to 1000 µM range which is beyond that of typical 
caffeine consumption (Tanaka et al., 1990).  
Adenosine.   As the main constituent of ATP, adenosine is present both 
intracellularly and extracellularly throughout the body. Although adenosine is an 
important modulator of neurotransmission, it is not considered a classical 
neurotransmitter because it is neither stored in vesicles nor dependent on Ca+ for release 
(Fisone et al., 2004). Instead, adenosine is transported between the cytoplasm and 
extracellular space through equilibrative nucleoside transporters. The direction of this 
transport is dependent on the adenosine concentration gradient in both sides of the 
membrane (Gu et al., 1995), which under normal conditions facilitates the intra-cellular 
transport of extracellular adenosine as adenosine is incorporated into AMP intracellularly 
via the enzyme adenosine kinase. During times of physiological stress, such as ischemia 
or hypoxia, intracellular levels of adenosine rise due to hydrolysis of ATP which 
subsequently fuels an increase in the extracellular concentration of adenosine (Wallman-
Johansson and Fredholm, 1994). Aside from adenosine efflux from the cytoplasm, a 
second minor source of adenosine exists in the extracellular space that involves the 
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conversion of released adenine nucleotides into adenosine by several enzymes 
(Zimmerman and Braun, 1999). 
 Rising extracellular levels of adenosine are thus viewed as a protective response 
from metabolic injury and various therapeutics have been proposed recently to 
specifically raise extracellular adenosine levels. In particular, the drug propentofylline 
has been forwarded as a potential treatment for Alzheimer’s disease, and it showed 
promising results in a clinical study (Kittner et al., 1997). One role of this drug is 
blockade of the equilibrative adenosine transporters, which leads to an increase in 
extracellular adenosine levels because of the conversion of adenine nucleotides into 
adenosine mentioned earlier. The elevation of extracellular adenosine levels 
downregulates activated glial cells and leads to the restoration of altered calcium 
homeostasis (Ringheim, 2000). Likewise, the drug dipyridamole blocks adenosine uptake 
and inhibits the enzyme adenosine deaminase that breaks down adenosine, thus leading to 
increased extracellular concentrations and has been shown to block the enhanced 
vasoconstriction induced by soluble Aβ by increasing cGMP activity (Paris et al., 1999). 
Adenosine itself is also administered commonly by paramedics as a treatment to slow 
atrial tachycardia by increasing conduction time through the AV node. Finally, it has also 
been found that long-term ingestion of caffeine in rats leads to significantly increased 
levels of adenosine in blood plasma in a dose-dependent manner through an unknown 
mechanism (Conlay et al., 1997). Although adenosine does not cross the blood brain 
barrier, it can be assumed a rise in brain adenosine levels should accompany rises in 
plasma adenosine levels because caffeine can enter the brain from plasma and exert 
similar effects on adenosine receptors there as well. 
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Adenosine Receptors.   Currently, four G-protein-coupled receptor (GPCR) 
subtypes have been identified to have adenosine affinity. These subtypes, named A1, A2A, 
A2B, and A3, are expressed throughout the brain in particular and in both the central and 
peripheral nervous system (Fredholm et al., 1994); they are collectively referred to as the 
P1 (adenosine selective) receptors. The high affinity receptors A1 and A2A are typically of 
interest because they are most likely responsible for the neuromodulatory effects of 
adenosine at physiological levels, while the lower affinity A2B receptors have been 
relatively ignored because they are most likely only activated when adenosine levels are 
increased (Fredholm et al., 1999; Fisone et al., 2004). The low affinity A3 receptors are 
sparsely distributed in humans and are little affected by caffeine or its metabolites in rats 
(Fredholm et al., 1999). Although A2B and A3 receptors cannot be completely excluded 
from having a neuroprotective effect in relation to caffeine, this is simply because 
evidence that might support such a role is lacking so these receptors are not included in 
this thesis. Refer to Figure 1 at the end of this section for an overview of caffeine-
mediated effects by adenosine receptor antagonism. 
 The A1 type adenosine receptors have high affinity for both caffeine and 
adenosine. These receptors are widely distributed in the brain, with higher expression in 
the cerebral cortex, cerebellum, hippocampus, and in the dorsal horn of the spinal cord 
(Ribeiro et al., 2003), while lower expression levels of this receptor are also found in the 
basal ganglia (Rivkees et al., 1995). These receptors (along with the A3 receptors) 
activate inhibitory G-proteins (both Gi and Go) which may lead to the inhibition of 
adenylyl cyclase, closure of Ca2+ channels (MacDonald et al., 1986), and activation of 
K+ channels (Trussel and Jackson, 1985). Inhibition of adenylyl cyclase ultimately leads 
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to decreased production of cAMP, thus activation of these receptors is generally thought 
to provide an inhibitory effect on secondary messenger systems while stabilizing the 
cellular membrane by blocking Ca2+ influx. 
The A1 receptor is present on the membranes of neurons, microglia, and 
astrocytes (Ongini and Schubert, 1998). The majority of neuronal adenosine A1 receptors 
are located on presynaptic nerve terminals where they provide inhibition of 
neurotransmitter release after activation by adenosine (Fisone et al., 2004), although 
some post synaptic A1 receptors may also exert an inhibitory effect (Ribeiro et al., 2003). 
Most importantly, activation of A1 receptors has been shown to limit neuronal release of 
the excitatory amino acid glutamate (Flagmeyer et al., 1997) and decreases in 
acetylcholine release have also been reported (Brown et al., 1990).  Activation of A1 
receptors in the striatum was also linked to inhibition of the D1 receptor-mediated 
increase in adenylyl-cyclase activation (Abbracchio et al., 1987), giving an explanation 
for the reports of decreases of striatal extracellular dopamine levels following A1 receptor 
activation (Okada et al., 1996). Caffeine administration would disinhibit these neurons, 
leading to an increase in neurotransmitter release (see Figure 1). 
The inhibitory effect of adenosine A1 receptor activation on glutamate release and 
Ca2+ influx likely is responsible for the neuroprotection (particularly in hippocampal 
regions) seen when animal models of cerebral ischemia are administered A1 selective 
adenosine receptor agonists (Rudolphi et al., 1989). The stabilization of Ca2+ homeostasis 
after A1 receptor activation raises the depolarization threshold needed to remove the Mg2+ 
blockade in NMDA receptors (present in large numbers in hippocampal neurons) leading 
to a reduced risk of excitotoxicity (Ongini and Schubert, 1998). Treatment with an A1 
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selective adenosine receptor antagonist on the other hand, is shown to exacerbate damage 
in the hippocampus during ischemia because of the increased exposure to excitotoxicity 
(Rudolphi et al., 1997). 
 The A2A type adenosine receptors also have high affinity for caffeine and are 
activated by the nanomolar concentrations of adenosine present during normal 
physiological conditions in the brain (Fisone et al., 2004). These receptors are highly 
expressed in the basal ganglia, particularly in the striatum, and the olfactory bulb, while 
much lower levels of this receptor are found in the hippocampus and cortex (Sebastiao 
and Ribeiro, 1996). The A2A receptors activate stimulatory G-proteins (Gs in the 
periphery and Golf in the striatum) which in turn activate adenylyl cyclase (Herve et al., 
2001) and may also activate voltage-sensitive Ca2+ -channels in certain cells (Fredholm et 
al., 1999). It has been shown in some hippocampal neurons that A2A receptor activation 
upregulates Ca2+ uptake via class A calcium channels, through the activation of adenylyl 
cyclase signaling (Goncalves et al., 1997). Notably, A2A adenosine receptors sometimes 
are located with A1 receptors on the same cells, indicating these different receptor types 
may have opposing roles when on the same cell. Indeed, in the striatum (a brain area 
where A2A receptors are high and A1 receptors are low) activation of the A2A receptor 
leads to a desensitization of the A1 receptor (Dixon et al., 1997). The end result of 
adenosine receptor activation thus may depend on the densities of each receptor type in 
that particular brain area. 
 A2A receptors are located on both neurons and microglia, but not on astrocytes 
(Fiebach et al., 1996). A2A receptors are also present on coronary arterial walls and upon 
activation cause vasodilation (Linden, 2001). In addition, A2A receptors are also located 
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in the periphery on bone-marrow derived cells; such as neutrophils, monocytes, 
macrophages, platelets, and mast cells, where in vitro activation of these receptors has 
been shown to reduce the release of reactive oxygen species and the pro-inflammatory 
cytokine TNF-α (Sullivan, 2003). An in vivo study confirmed that genetic inactivation of 
A2A receptors in the periphery results in the loss of a negative feedback mechanism that 
would otherwise limit a systemic inflammatory response and reduce tissue damage (Ohta 
and Sitkovsky, 2001). This suggests that A2A receptor activation potentially might reduce 
the pro-inflammatory component of the amyloid cascade in the brains of Alzheimer’s 
afflicted patients. Expression of A2A receptor mRNA on glial cells in the brain is limited 
however (Schiffman et al., 1991), thus their role in any A2A-modulated actions is unlikely 
to be significant. Therefore, blockade of glial A2A receptors by caffeine would also be 
limited so it should not have a noticeable effect on inflammation in Alzheimer’s disease 
(see Figure 1). 
Activation of A2A receptors by selective A2A receptor agonists has shown 
significant increases in extracellular glutamate levels in the striatum (Popoli et al., 1995) 
and cerebral cortex (O’Regan et al., 1992), providing evidence that activation of striatal 
A2A adenosine receptors gives a detrimental effect during times of ischemia and/or 
excitotoxicity in direct contrast with A1 receptor-mediated protection. Accordingly, A2A 
receptor blockade by selective A2A adenosine receptor antagonists has been found to 
reduce neuronal striatal damage induced by the excitotoxin quinolic acid (Popoli et al., 
2002) and A2A receptor KO mice have been reported to be protected against MPTP-
induced neuronal damage in the striatum (Chen et al., 2001). With this information in 
mind, any neuroprotective effects of A2A antagonists against Alzheimer’s are likely due 
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to vasodilatation in the periphery, rather than in the brain itself because excitotoxic 
damage is not indicated in striatal areas in patients with this particular disease. 
Particularly in Parkinson’s research, neuronal A2A receptors have received intense 
interest because of their roles in dopaminergic transmission in the dopamine rich areas of 
the striatum. The majority of striatal A2A expression is found in association with the 
inhibitory dopamine activated D2 receptors on the GABAergic medium-sized neurons of 
the indirect pathway that project from the striatum to the globus pallidus and subthalamic 
nucleus (Ferre et al., 1997). Under normal conditions, dopamine is the major modulator 
of this pathway, with A2A receptors playing an opposing role to activation of the 
inhibitory D2 receptors. When dopamine levels diminish in Parkinson’s disease, this 
GABAergic/globus pallidus/subthalamic nucleus pathway is overactive, contributing to 
the motor abnormalities present in this disease. Thus A2A specific antagonists have been 
forwarded to potentially correct this imbalance, in addition to their neuroprotective effect 
mentioned earlier. While this information is important for potential therapeutics against 
the degeneration of the dopaminergic system seen in Parkinson’s disease, it is unlikely to 
have much bearing in Alzheimer’s disease. 
Caffeine Intake
A1 Receptor Antagonism A2A Receptor Antagonism
Unknown
↓ cAMP
↓ Glutamate release
↓ GABA
↑ Dopamine release
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↑ Vasoconstriction
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Unknown
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mediated effects of 
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Immediate Effects of Caffeine Intake 
Physiological Changes.    The initial absorption of caffeine into the bloodstream 
creates widespread changes throughout the CNS. Acute doses of caffeine lead to 
increases in cerebral energy metabolism in areas of the brain responsible for motor 
activity and the sleep cycle, and this response is not abolished by any appearance of 
tolerance (Fredholm et al., 1999). Surprisingly, this increase in cerebral metabolism is 
also accompanied by a decrease in cerebral blood flow due to the cerebral 
vasoconstriction induced by caffeine seen during rest (Higashi et al., 2004). Caffeine’s 
effect on alertness is positive however, so it is likely that any increases in metabolism 
with reduced blood flow are met with increased glucose utilization. Interestingly, 1-5 
mg/kg doses of caffeine in rats leads to widespread increases in glucose utilization 
throughout the brain, including areas of the cortex, hippocampus, and central components 
of the nigrostriatal dopaminergic system (Nehlig and Boyet, 2000). A caffeine-induced 
 38
 39
increase in metabolism coupled with decreased blood flow could potentially lead to 
increased levels of extracellular adenosine in an ischemic-like response. 
 In the absence of caffeine, adenosine levels increase during prolonged 
wakefulness which suppresses cortical activity by activating the inhibitory A1 receptors 
on mesopontine cholinergic neurons (Rainnie et al., 1994). The increase in cortical 
activity following caffeine intake evident in the electroencephalogram (EEG) as 
decreases in delta and theta waves and an increase in alpha and beta waves (Patat et al., 
2000) is thus linked to caffeine’s antagonism of A1 receptors on these particular neurons. 
Caffeine also decreases GABA release in the globus pallidus, leading to increased 
activity in this region as well (Fredholm et al., 1999). Furthermore, a microdialysis study 
with rats found that caffeine administration dose-dependently raised dopamine and 
acetylcholine concentrations in the prefrontal cortex (Acquas et al., 2002). The authors 
also reported the increases in dopamine concentrations were lost after tolerance 
developed to chronic caffeine treatment, while caffeine’s affects on acetylcholine were 
not. This information lends support to the reported positive affect of caffeine on alertness 
that is not lost in chronic caffeine users. 
Behavioral Effect.   Although acute use of lower doses of caffeine is known to 
promote locomotor effects in caffeine intolerant rodents, the exact mechanism for this 
action remains to be clearly pinpointed to one receptor. Acute doses of caffeine given in 
mice in particular are reported to decrease exploratory behavior in the open field (Meyer 
and Caston, 2004) and increase anxiety in the plus-maze task (Silva and Frussa-Filho, 
2000). Given that A2A receptors are found in particular abundance in the striatum (an area 
of the brain profoundly involved in locomotion) it has generally been assumed that 
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blockade of A2A receptors following caffeine administration is mainly responsible for the 
changes in locomotor activity (see Table 1). Concordantly, it is not surprising that A2A 
receptor KO mice are resistant to the stimulatory effects of caffeine (Halldner et al., 
2004). 
  Caffeine also is reported both anecdotally and experimentally to provide an 
immediate positive effect on learning and memory. It is interesting to note that a study 
found an acute dose of caffeine administered to caffeine-naïve rats after training in the 
Morris water maze improved their reference memory in the probe trial at doses of 0.3-10 
mg/kg, whereas a higher does of 30 mg/kg had no effect on performance (Angelucci et 
al., 2002). Acute caffeine doses of 0.1-0.3 mg/kg also were also found to reverse memory 
disruption in the two-way active avoidance task induced by MPTP injections in rats 
(Gevaerd et al., 2001). Additional studies found that administration of an A1 specific 
receptor antagonist MDL102503 to rats reverses scopolamine-induced memory 
impairment in the water maze. In addition, another A1 specific receptor antagonist 
(KFM19) also improved performance in other cognitive based tasks, such as the Y-maze 
(Jacobson et al., 1996). Castellano (1976) also found a caffeine dose of 1 mg/kg to mice 
improved the learning and consolidation processes in a Y water maze task. 
Although these studies give evidence for a potential positive effect on memory by an 
acute dose of caffeine in rodents, they don’t provide much insight into the effect a long-
term treatment of caffeine might have on memory and learning in rodents. Furthermore, it 
is also difficult to tell if improved performance in these cognitive tasks following acute 
doses of caffeine is simply related to increased alertness in these mice and not an increase 
in memory or learning. For instance, caffeine doses of 2.5 and 5 mg/kg had no effect on 
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avoidance learning of mice in the shuttle-box avoidance test, while caffeine doses of 10 
mg/kg actually impaired their performance (Sansone et al., 1994). Similar results were 
found by Izquierdo et al (1979), who found mice administered 29.9 mg/kg of caffeine 
were significantly impaired in their memory retention in the passive avoidance task. It is 
likely alertness is less of a component in mouse performance in the avoidance tasks, 
because these tasks utilize a conditioned response rather than the reliance on spatial cues 
for orientation in the Morris water maze. Lastly, a study using wild type rats found that 
acute doses of caffeine improve tracking performance, indicating improved alertness 
(Evenden et al., 1993) (see Table 1 for a summary of these results). 
 Controlled human studies have produced mixed results. James (1998) reported no 
effects of caffeine on performance were seen when administered on either an acute or 
chronic basis. This study did find participants were more alert and less tired following 
acute intake of caffeine, but felt less alert following chronic exposure to it. A study that 
stratified the dose-dependent effects of caffeine found caffeine administered at a lower 
dose (250 mg) produced pleasant subjective feelings and positive effects on performance 
whereas a higher dose (500 mg) produced unpleasant subjective feelings and decreased 
performance (Kaplan et al., 1997). Differences in performance were also reported 
between studies using low dosages of caffeine. A low dose of caffeine (100mg) failed to 
have an effect on short or long-term memory retrieval in middle to elderly men and 
women (Schmitt et al., 2003). A study utilizing a CANTAB battery found 60 mg of 
caffeine sped up reaction times in pattern recognition, delayed match to sample, and 
match to sample visual searches (Durlach et al., 1998). Both of these studies are similar 
however because they included habitual caffeine users forced to abstain from caffeine for 
the study purposes. This is significant because another study reported the caffeine-
induced increase in a sustained attention task was abolished when the moderate caffeine 
users were tested after no longer being deprived of caffeine (Yeomans et al., 2002). The 
authors go on to theorize that caffeine’s beneficial affect on memory is mainly due to 
withdrawal reversal, a likely suggestion supported by information gleamed from animal 
studies dealing with acute or chronic doses of caffeine. 
Table 1. Immediate Effects 
of Moderate Caffeine Intake
Rodent Cognition*
UnknownImproved reference memory (Morris water maze)
Striatal A2A antagonismIncreased anxiety
UnknownImproved learning/consolidation (Y water maze task)
Mesopontine Cholinergic A1 antagonismIncreased cortical EEG activity
A1 antagonismNeurotransmitter Disinhibition
Mesopontine Cholinergic A1 antagonismIncreased alertness
General Behavior (Humans and Rodents)
UnknownIncreased glucose utilization
Global vasculature A2A antagonismCerebral Vasoconstriction
Receptor ActionPhysiological
* Improved cognition may be due to increased alertness  
Long-Term Effects of Caffeine Intake 
Behavioral Effect (Rodents).    The locomotor disturbances induced by acute 
doses of caffeine disappear after chronic caffeine administration. For instance, rats given 
an acute dose of caffeine show decreased exploratory behavior in the open field task and 
also show increased anxiety in the plus-maze test; yet after 21 days of chronic caffeine 
administration both of these disturbances disappear (Bhattacharya et al., 1997). Another 
study reported that tolerance to A1 receptor blockade is indicated for the lack of 
consistent locomotor disturbances after caffeine intake in caffeine tolerant individuals 
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(Karcz- Kubicha et al., 2003). Overall, these animal studies point to a minimizing or 
complete loss of the motor effects of caffeine once tolerance develops. 
 The chronic administration of caffeine to rodents leads to adaptive changes that 
abolish the cognitive changes seen during acute treatment of caffeine as well. Chronic 
administration of the A1 selective receptor antagonist CPX for only 9 days resulted in a 
tolerant adaptation that caused CPX to have no effect on the spatial learning and memory 
of mice tested in the Morris water maze (Von Lubitz et al., 1993). Chronic caffeine 
treatment for 15 days also had no effect on prevention of memory loss in trained rats 
(Molinengo et al., 1994). Prior studies in wild-type rodents thus have shown that 
administration of caffeine or specific adenosine receptor antagonists for approximately 
two weeks results in no obvious effects on memory or learning, although no truly chronic 
caffeine administration studies (that might relate to caffeine use in humans) have been 
done investigating cognitive measures. 
Behavioral Effect (Humans).    Large population studies done to examine the 
long-term effects of caffeine use on human memory have been controversial because of 
the many variables that must be taken into account. For instance, Hameleers et al. (2000) 
found in a cross-sectional study of 1875 adults participating in the MAAS study (the 
Maastricht Aging Study) and ranging in age from 24-81 years that higher habitual 
caffeine intake is significantly associated with faster response speed and improved long-
term memory, yet no differences in short-term memory were found. In contrast, a 
longitudinal study of the same MAAS group found no relationship between habitual 
caffeine intake and verbal memory performance (van Boxtel et al., 2003). An earlier 
study of 9003 British adults reported that aged individuals appear to be more receptive to 
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caffeine’s cognitive boosting affects than younger individuals (Jarvis, 1993), thus 
suggesting that the inclusion of younger adults in the MAAS studies may have provided 
the confounding results. 
Physiological Changes of Long-Term Caffeine Intake.    The study by Maia and 
Mendonca (2002) that suggested caffeine intake is associated with a lower risk for AD 
has driven several studies to investigate caffeine’s antagonism of specific adenosine 
receptors in the CNS, the more obvious effect of caffeine intake (Dall’Igna et al., 2004; 
Dall’Igna et al., 2003) . These studies fail to fully account for the typical patterns of 
caffeine consumption in humans however. Knowing that caffeine’s half-life in humans 
can be less than 3 hours, it is reasonable to assume that the short term effects of caffeine 
intake only exist for brief durations during the typical day. This makes it difficult to 
attribute an overall protection against AD (which is progressively and continually 
disrupting the normal brain physiology decades before any symptoms appear) to the 
immediate blockade of adenosine receptors. It is therefore relevant to look to any long 
term effects of caffeine as the main agent granting protection from AD. From this 
standpoint, caffeine’s neuroprotective effect can be elucidated from several studies 
indicating an effect of caffeine on adenosine modulation separate from acute receptor 
antagonism. These are significant because relationships between impaired adenosine 
levels and Alzheimer’s disease have already been implicated but not completely 
explored. 
It is particularly noteworthy that increased plasma levels of homocysteine, a 
known risk factor for AD, are associated with decreased adenosine formation in plasma 
taken from AD patients (Selley, 2004). Interestingly, increased levels of homocysteine 
are associated with normal aging, decreased physical activity, and diets high in animal 
protein yet deficient in fruits and vegetables (Miner et al., 1997). These are all also risk 
factors for AD. 
At the molecular level, high levels of homocysteine interfere with the intracellular 
production of adenosine by forcing the normal conversion of S-adenosylhomocysteine 
(SAH) into adenosine and L-homocysteine to occur in reverse, thus sequestering 
adenosine as SAH inside the cell (Fredholm et al., 1999; Fig.2). Indeed, high levels of 
SAH have recently been identified in the brains of AD patients, and elevated levels of 
SAH in AD patients have been shown to inhibit important methyltransferases in the brain 
(Kennedy et al., 2004). Furthermore, the enzyme S-adenosylmethionine (SAM), which is 
involved in the continuous conversion of methionine to homocysteine (Miner et al., 
1997), is found in decreased concentrations in Alzheimer’s disease (Morrison et al., 
1996; Morris, 2003; Mizrahi et al., 2003). The SAM enzyme has recently been identified 
as a methyl donor to a promoter site on the PS1 gene resulting in decreased PS1 
expression (Scarpa et al., 2003), and also is involved in the down-regulation of BACE (β-
secretase) (Fuso et al., 2005) (Fig. 2). 
S-adenosylhomocysteine(SAH)
Figure 2. Impact of elevated 
levels of homocysteine on 
SAM in AD
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If high levels of homocysteine are present, either because of diet, vitamin 
B12/folate deficiency, or advancing age; then it is likely that SAM methylation of PS1 and 
BACE is blocked by the increased concentrations of SAH. Thus, decreasing methylation 
by SAM may result in a rise in expression of the PS1 and BACE genes, leading to 
increases in Aβ production. It has also been found through in vitro studies that a folic 
acid deficiency and elevated homocysteine levels disrupt DNA repair in hippocampal 
neurons, which sensitizes them to the toxic affects of amyoid accumulation (Kruman et 
al., 2002). This information implies that increased homocysteine levels may play both a 
direct and indirect role in Alzheimer’s disease, and represents a potential target for the 
long-term effects of caffeine intake (see Figure 3). 
Interestingly, a recent in vivo experiment found extracellular levels of adenosine 
were elevated 8 hours after caffeine administration in rats (Conlay et al., 1997). The 
authors proposed this increase may be a result of adenosine receptor blockade. However, 
caffeine is the downstream precursor of a biosynthetic process in tea leaves that begins 
with SAM (Koshiishi et al., 2001). Thus, caffeine intake may elevate SAM levels when it 
is degraded. It is also possible that caffeine’s blockade of A2A receptors on astrocytes 
leads to inhibition of COMT (catechol-O-methyltransferase), the enzyme responsible for 
conversion of SAM to SAH. The elevation of SAM would lead to the decreased 
expression of the genes that would otherwise lead to AD (see Figure 3) and might be 
evident by increased adenosine levels as SAH was hydrolyzed to adenosine and 
homocysteine. 
S-adenosylhomocysteine(SAH)
Figure 3. Proposed impact 
of caffeine on the SAM/SAH 
cycle in AD
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Tolerance to Caffeine 
The long-term administration of caffeine results in the disappearance of the 
behavioral side effects associated with caffeine intake (e.g. tolerance). Concordantly, this 
should be the result of neuromolecular changes because of the fluctuating presence of 
caffeine and elevation of adenosine levels. Indeed, numerous studies involving rodents 
have reported that chronic treatment with caffeine, ranging from 4-28 days, results in 
increased numbers of A1 receptors in both cortical (Tsutsui et al., 2004; Shi and Daly, 
1999; Shi et al., 1993) and hippocampal neurons (Rudolphi et al., 1989; Johansson et al., 
1993). The mechanism for this increase remains unresolved, as none of these studies 
reported changes in mRNA for the A1 receptor. Many of these studies examined A2a 
receptors as well, but no changes were seen in receptor counts or mRNA levels (Shi and 
Daly, 1999; Johansson et al., 1993; Shi et al., 1993). These findings suggest A1 receptors 
are responsible for the development of tolerance to the behavioral and physiological side 
effects of caffeine. Importantly, this increase in A1 receptor levels has implications for 
potentially reversing trends seen in AD as well. Additionally, a 4-day treatment of 
caffeine to mice also found an approximate 17% increase in the density of cortical L-type 
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calcium channels, but the authors failed to suggest a mechanism for this and its 
implications remain unknown (Shi et al., 1993). 
The considerable 8 hour delay between caffeine administration and increases in 
adenosine first noticed by Conlay et al. was later replicated and traced to the blockade of 
A1 receptors (Andresen et al., 1999). The authors suggested the time lag between receptor 
antagonism and increases in adenosine may be caused by new protein synthesis, post-
translational modifications, or reductions in the synthesis of key enzymes responsible for 
metabolizing adenosine, such as adenosine deaminase. The authors go on to propose that 
A1 receptors monitor extracellular levels of adenosine and when activated, influence 
adenosine levels by potentially modulating the activity of adenosine deaminase. 
Therefore the losses in hippocampal A1 receptors reported in patients with dementia 
(Deckert et al.., 1998) and Alzheimer’s disease (Ulas et al., 1993) suggests impaired 
monitoring of adenosine function in AD. If adenosine is being trapped intracellularly in 
the form of S-adenosylhomocysteine, then the reduction of extracellular adenosine could 
potentially lead to the reductions in its receptor as well. Given the likely role of APP in 
axonal transport (Kamal et al., 2001) and accumulating Aβ interferes with fast 
anterograde and retrograde axonal transport (Hiruma et al., 2003), it is also possible to 
surmise impaired axonal transport may lead to the decrease in adenosine A1 receptors 
seen in AD cases. 
Diminishment of A1 receptor function would impair an innate neuronal pathway 
that monitors Ca2+ homeostasis, which is known to be disrupted in neurons after long 
term exposure to the Aβ1-42 isoform found in AD. As mentioned earlier, NMDA receptors 
are found in abundance in the hippocampus making neurons in this area particularly 
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sensitive to excitotoxic damage during pathological conditions. Therefore, it is likely that 
the progression of AD leads to decreases in A1 receptor-mediated protective mechanisms 
against excitotoxicity in both the cerebral cortex and hippocampus in combination with 
the toxic affects of Aβ, creating a hostile environment for neurons in these brain areas. 
An increase in A1 receptors following long term treatment of caffeine thus may reverse 
this trend restoring A1 receptors to normal or above physiological levels. 
Health Risks of Caffeine Intake 
 The impact of moderate caffeine intake on health has been scrutinized through 
epidemiological studies with no clear detrimental affects. Caffeine’s relationship with 
blood pressure is of particular concern, yet most studies report no association between 
caffeine consumption and blood pressure in tolerant individuals (Chou and Benowitz, 
1994; Robertson et al., 1984; Bertrand et al., 1978). Other studies have found an 
association between caffeine and changes in blood pressure, but these findings are 
considered controversial because they fail to distinguish between infrequent caffeine 
users and habitual caffeine users (Rachima-Maoz et al., 1998). It has also been suggested 
that hypertensive patients are more prone to the pressor effects of caffeine, although this 
sensitivity was not found in a case study (Robertson et al., 1984). Moderate caffeine 
intake is known to raise blood pressure in caffeine-naïve subjects and in subjects 
abstaining from caffeine long enough to lose their tolerance to caffeine, yet this pressor 
affect is only in the range of 2-3 mm Hg and this affect is lost within 24 hours after 
tolerance appears (Myers, 2004). High intake of caffeine also can lead to tachycardia, 
heart palpitations, and a small decrease in heart rate, but again these effects are 
minimized after tolerances develops within days (Fredholm et al., 1999).  
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The Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure expressed their view that restriction of caffeine intake 
is not a recommended procedure on reducing blood pressure (Chobanian et al., 2003), yet 
some doctors continue to recommend the elderly or people already prone to hypertension 
avoid caffeine. If caffeine does have neuroprotective properties, it would be prudent 
instead to recommend a moderate, sustained caffeine intake throughout life to reduce any 
of the cardiovascular effects discussed previously that could appear if tolerance to 
caffeine is lost during any abstinence from the drug. 
 Caffeine, as well as other methylxanthines, is a well known diuretic and 
natriuretic that inhibits proximal tubular reabsorption by antagonizing renal A1 receptors 
(Rieg et al., 2004). Finally, caffeine also raises the respiratory rate in the same, but yet 
not as effective, mechanism as theophylline (the common bronchodilator prescribed for 
asthmatics) (Benowitz, 1990). Caffeine also has weak self-reinforcing properties when 
compared to the drugs of abuse, such as cocaine or heroine, and is not described as an 
addictive substance in the Diagnostic and statistical manual of mental disorders (4th ed.).  
Although symptoms such as headache and fatigue may accompany caffeine withdrawal 
when caffeine intake is reduced significantly (Griffiths et al., 1990), none of the side 
effects of prolonged, moderate caffeine intake have been linked conclusively to any 
adverse health conditions. 
Summary 
 Although blockade of A1 and A2A adenosine receptors produces some potential 
immediate neuroprotective effects, it is likely that caffeine’s biggest contribution to 
neuroprotection in Alzheimer’s disease may be the reinforcement of SAM methylation of 
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PS1 and BACE. Given the nature of moderate caffeine consumption and its metabolism, 
the short-term neuroprotective effects of caffeine would certainly not exist long enough 
to have any lasting contribution against the lifelong onslaught of AD. Although it has yet 
to be determined exactly how caffeine raises SAM levels, several possibilities exist. First, 
caffeine is a xanthine derivative of SAM, and once metabolized may provide extra 
substrate for the synthesis of SAM, leading to the increased formation of this compound. 
Caffeine may also inhibit COMT activation, which would decrease astrocytic 
homocysteine synthesis (Huang et al., 2005) and reduce SAM conversion to SAH. 
Regardless, the chronic use of caffeine generates a rise in SAM that likely leads to 
diminished expression of genes that are known to be overexpressed in familial 
Alzheimer’s disease and are likely askew in sporadic AD, resulting in decreased 
production of Aβ and prevention of the corresponding changes in neuropathology. 
Ideally, changes in expression of these genes is minimal but sufficient enough to slow 
down Aβ production thus avoiding many of the negative side effects of other therapeutics 
designed to minimize expression of these genes. It is also possible that diminished 
production of Aβ allows for innate protective mechanisms in the body to equilibrate the 
clearance and production of Αβ. Caffeine may also be effective in reversing the decreases 
in hippocampal A1 receptors seen in AD and aging through mechanisms that develop as 
tolerance in response to chronic caffeine intake, ultimately restoring the endogenous 
protective pathway against alterations in Ca2+ or excitotoxicity. 
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IV. Specific Aims 
 Overexpression of the hAPP gene with the “Swedish” double mutation in APPsw 
mice results in impaired reference/learning memory and impaired working memory by 8-
9 months of age that closely mimics the cognitive decline seen in Alzheimer’s patients. 
These behavioral impairments are certainly linked to the appearance of Aβ species, but 
other pathological changes must also be taken into consideration as well when evaluating 
the full scope of the disease. The decrease in A1 adenosine receptors found in the brains 
of late Alzheimer’s patients may be a marker for other important disruptions in the brain, 
especially considering adenosine’s relationship with homocysteine/SAH/SAM and its 
potential indirect impact on enzymes reported to decrease expression of genes involved in 
AD. SAM-related changes have yet to be examined in animal models for Alzheimer’s 
disease, so it is therefore relevant to see if there are any differences between APPsw and 
non-transgenic mice. 
 Caffeine use has been implicated with the occurrence of Alzheimer’s disease, 
with moderate caffeine intake decreasing the risk for the disease. Additionally, caffeine 
use has been shown to increase cortical and hippocampal A1 receptors and raise 
extracellular adenosine levels in blood plasma. If this occurs in the brain, it may further 
support the link between impaired SAM function and Alzheimer’s disease. I propose that 
APPsw mice will have decreased cortical and hippocampal A1 receptors and subsequently, 
will also have reduced extracellular brain adenosine and S-adenosylmethionine levels in 
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the brain. These APPsw mice will also be cognitively impaired because of increased levels 
of soluble Aβ. Furthermore, long-term administration of a moderate caffeine dose to 
APPsw mice will reverse these effects, ultimately reducing amyloid load in these mice and 
restoring cognitive function. 
The specific aims of my research proposal are: 
• To behaviorally characterize a group of APPsw and Tg- control mice in a full 
battery of sensorimotor and cognitive tasks to determine the degree of behavioral 
impairment these mice develop at 8 months of age. 
• To determine the behavioral effect a 4 month treatment of oral caffeine 
(beginning at 4 months of age) has on a similar group of age-matched 8 month old 
APPsw transgenic mice. 
• To explore any differences in SAM and adenosine between non-transgenic and 
APPsw mice.  
• To evaluate the relationship between long-term caffeine administration in a mouse 
model of Alzheimer’s disease and any changes in amyloidogenic processing in 
the CNS as a result of caffeine treatment.  
• To determine the relationships between brain Aβ levels, brain adenosine receptor 
levels, and cognitive performance in APPsw and caffeine-treated APPsw transgenic 
mice. 
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V. Materials and Methods 
Animals 
57 mice were included in this study. Each mouse had a mixed background of 
56.25% C57, 12.5% B6, 18.75% SJL, and 12.5% Swiss-Webster. All of these mice were 
derived from a cross between P (parental generation) heterozygous male mice carrying 
the mutant APPK670N, M671L gene (APPsw) with F1 PS1 (transgenic line 6.2) female mice to 
obtain an F2 generation consisting of APP/PS1, APPsw, PS1, and non-transgenic mice. 
After weaning, the mice were genotyped with only APPsw and non-transgenic mice 
selected for behavioral testing and/or caffeine administration. These mice were then 
group housed in cages with rodent chow and water or caffeinated water ad libum. All 
mice were maintained in a 10 hour dark and 14 hour light cycle at all times, and all 
behavioral testing was performed during the light cycle. 
Effects of Long-Term Caffeine Administration in Young Adult APPsw Mice 
General Protocol 
 A total of 41 single transgenic APPsw mice and 16 non-transgenic (NT) littermates 
were randomly selected for this study. 14 APPsw mice were randomly selected from the 
APPsw group and were administered caffeine treatment in drinking water beginning at 4 
months of age. The remaining 27 transgenic mice, as well as 16 non-transgenic 
littermates, were provided normal water to serve as Tg and NT controls. All mice were 
removed from group housing and moved to single housing two weeks before behavioral 
testing began. Behavioral testing began at 8 months of age (four months into caffeine 
treatment) and consisted of a 6-week battery that was composed of 3 sensorimotor-based 
tasks, one anxiety-based task, and five cognitive-based tasks. These tasks were performed 
in the following order: open field activity, balance beam, string agility, Y-maze, elevated 
plus maze, Morris water maze, circular platform, platform recognition, and radial arm 
water maze. All mice were euthanized following completion of behavioral testing and 
brains were removed for further analysis. This analysis consisted of quantification of 
brain soluble/insoluble Aβ levels, determination of both α- and β-CTFs, and assessment 
of brain adenosine receptor densities. Fig. 1 depicts a timeline for this study. Mice were 
weighed every two weeks to ensure no changes in weight occurred from the caffeine 
treatment. 
Study Timeline 
6-Week Behavioral Battery 
Oral Administration 
of Caffeine 
Animals 
Sacrificed 
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Fig 4. General protocol time line for long-term caffeine administration study. 
 
Animals Born 
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Caffeine Treatment 
 At 4 months of age, 14 APPsw group housed mice were given ad libum access to 
only water with 0.3 mg/mL caffeine (Sigma) dissolved in it. On average, mice drink 5 mL 
per day, giving a daily dose of 1.5 mg of caffeine to each mouse. Given that metabolic 
rate (MR) =Mass-¼, the MR of mice (average weight = 0.025kg) is 7.2 x greater than 
humans (average weight = 68kg). Thus, a 1.5 mg daily dose in a mouse is equivalent to 
an approximately 500 mg daily caffeine intake (~5 cups of coffee) by a human. The 
caffeinated water was changed two times a week to ensure caffeine remained fully 
dissolved at the appropriate concentration. Control APPsw and NT mice were given ad 
libum access to untreated tap water that was also changed twice weekly to ensure 
freshness. Mice were kept under these conditions for 3½ months, at which point they 
were separated into single housing, two weeks before behavioral testing began (Fig. 1). 
Caffeine treatment was continued throughout this time and during behavioral testing. The 
weights of the animals were monitored throughout this study to ensure no significant 
weight reductions occurred. 
Behavioral Assessment 
Over a 6-week time course, mice were behaviorally tested for characterization of 
their sensorimotor, anxiolytic, and cognitive functions utilizing the following tasks and in 
the order described: 
Open-Field Task.    This test assessed exploratory behavior and activity by 
placing mice into an unfamiliar open black box (81 x 81 cm) with 28.5-cm walls. The 
bottom of the box was marked by 4 horizontal and 4 vertical lines, dividing the surface 
into 16 squares. The task consists of a single trial, wherein a single mouse is placed in the 
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center of the field and allowed to explore for 5 minutes. During this period, each line 
crossing was recorded. Before each trial, the surface of the box was sprayed with a 
diluted vinegar solution to erase any scent cues. 
Balance Beam Task.    The balance beam consists of a 1.1-cm-wide dowel beam 
suspended 43 cm above a padded surface. Flanking each end of the 51-cm-long dowel are 
14 x 10.2 cm platforms. Each animal was placed perpendicular to the dowel at the center 
of the beam and released for an interval of 60 seconds. The duration the animal was able 
to stay on the balance beam was recorded. If the animal remained on the balance beam 
for the full time and/or escaped to one of the platforms, the maximum score of 60 
seconds was recorded. Each mouse’s balance and general motor function was evaluated 
by subjecting the animals to 3 trials, with the overall average indicating the best 
approximation of the mouse’s performance. 
String-Suspension Task.    This task is an additional sensorimotor test used to 
characterize the agility and grip strength of mice. Animals were allowed to grip the string 
with only their forepaws and released for a single trial of 60 seconds. Each animal was 
scored on a 0-5 rating system (0=animal was unable to stay on the string; 1=animal was 
able to hang onto the string for 60 s by only two forepaws; 2=was given if the animal was 
able to hang onto the string by two forepaws and one hind limb; 3= animal remained on 
the string for 60 s and gripped the string by two forepaws and both hindpaws, 4=animal 
was able to grip the string with four paws and its tail; 5=was given if the mouse escaped 
from the string to one of the support columns. 
Y-Maze Task.   This task was used to assess basic mnemonic processing (by 
spontaneous percent alternation) and exploratory activity (by total number of arm 
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choices) of mice placed into a black Y-maze. The arms of this maze were 21 cm-long and 
4 cm-wide with 40 cm-high walls. Each mouse was placed in the center of the maze, 
facing the arm designated number two and allowed one five minute trial of free 
exploration of the three alleys in the maze. The number of total arm choices and sequence 
of arm choices were recorded. Alternation percentage is defined by the proportion of arm 
choices that differ from the last two choices. For instance, if a mouse selected the 
following sequence of arm choices (1,2,3,1,3,1,2,1), the total number of alternation 
opportunities would be six (total entries minus two) and the percentage alternation would 
be 50% (three of six). Before each trial, the interior of the maze was spray with a diluted 
vinegar solution to erase any scent cues. 
Elevated Plus-Maze.    The elevated (+)-maze was used to assess anxiety in mice. 
The task has four arms (30 x 5 cm) attached to a 5 x 5 cm central area, all made of 
plywood and painted black. Two opposite facing arms were unenclosed and open to the 
surrounding environment. The other two opposite facing arms were enclosed by black 
aluminum sheet walls (15-cm height). This entire structure sits on a wooden pedestal, 
elevated 82 cm above the floor level. Each mouse was placed into the center area facing a 
closed arm and allowed to explore the plus-maze for a single five minute trial. The 
number of closed and open arm entries, and the amount of time spent in open arms was 
recorded. Before each trial, the maze was cleaned with a diluted vinegar solution to erase 
any scent cues. 
Morris Water Maze.    This water-based task was used to evaluate spatial 
reference learning/memory of the mice. A 100-cm circular inflatable pool was divided 
into four equal quadrants by black lines drawn on the floor of the pool; an indiscernible 
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9-cm platform was submerged 1.5 cm below the water’s surface in quadrant two. The 
environment surrounding the pool was decorated with eye-catching visual cues to aid the 
mice in orientating themselves with respect to the pool. Each mouse was subjected to 
four trials a day over a 10 day period. Each trial began by placing the mouse into a 
different quadrant and allowing it to swim freely for a maximum of 60 seconds. The same 
quadrant start pattern was used each day. After swimming to the platform (or being 
guided to the platform if the mouse was unable to locate the platform after 60 s), the 
animal was allowed to remain on the platform for 30 s before starting the next trial. The 
latency for each animal to locate the platform in all four trials and the average for all 
trials was recorded. After the tenth day of acquisition testing, a 60 s probe trial was 
performed the following day to determine memory retention. For this single trial, the 
submerged platform was removed and each mouse was placed into the quadrant opposite 
to the quadrant that formerly contained the platform in acquisition testing. The animal’s 
swim path and number of annulus crossings were recorded on videotape; the percent of 
time spent in each quadrant, as well as average swim speed, were determined from these 
videotapes. 
Circular Platform Task.    This task tests reference learning/memory by placing 
the mice in a curtain-enshrouded 69-cm circular platform with 16 holes (4.5 cm diameter) 
equally placed 1.3 cm from the outside edge. The holes designated 4, 8, 12, and 16 
allowed the placement of an escape box directly underneath the hole. Two-dimensional 
cues were placed on the inside walls of the enclosing curtain, as well as on the platform’s 
walls. The aversive light and wind stimuli used to motivate mice to escape the platform 
was provided by two 150-W lamps placed 76 cm above the platform and a high-speed fan 
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placed 15 cm above the platform. The first day of the circular platform task consisted of 
shaping (wherein mice were placed into the center of the platform and gently guided to 
the location of their escape platform), with the following eight days designated for actual 
testing. The mice were subjected to a single trial each day that consisted of placing each 
mouse in the center of the platform and allowing it a 5 minute maximum to locate and 
enter the escape box. During the testing period, the total number of errors (head pokes 
into non-escape holes) and the latency to escape from the platform were recorded. The 
surface of the circular platform was cleaned after each trial with a dilute vinegar solution 
and the escape box location was moved to a different location after each mouse’s trial to 
control for any scent cues (although the box remained in the same location for each 
particular animal over the eight days of testing). 
Platform Recognition Task.    This water-based task characterizes the ability of 
the mice to escape to a visible platform in changing locations placed in the same 100-cm 
inflatable water pool used in the Morris water maze. A delayed latency to escape 
indicates a potential deficit in visual acuity or, more likely, an impaired ability to switch 
strategies from a spatial cued strategy used in the Morris water maze to a 
search/recognition strategy needed for this test. In this task, a 9-cm circular escape 
platform was elevated 0.8 cm above the surface of the water with an affixed 10 x 40 cm 
black and white visual cue to clearly mark it as the escape platform. Performance was 
evaluated over four days of testing, with 4 trials per day. Each day, the mice were placed 
in the pool at the same location for each trial, but the platform was moved successively to 
a new quadrant for each of the four trials. If a mouse was unable to locate the platform in 
the 60 s provided, it was gently guided to the platform. A 30 s rest period was given to 
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each mouse on the platform. Latency to find the platform was recorded over all 4 trials 
each day, which were averaged for statistical evaluation. 
Radial Arm Water Maze (RAWM).    This final water-based task requires the mice 
to have intact working (short-term) memory and is the most stringent for determining 
cognitive deficiencies. The RAWM maze incorporated the same 100-cm circular pool 
used previously, but also used an aluminum insert that creates 6 equal-sized radial arms 
surrounding a central open swimming area 40 cm in diameter. Each arm was 30.5 cm 
long and 19 cm wide, and a transparent 9 cm circular platform that rests 1.5 cm below the 
water’s surface was placed near the end of the randomly assigned goal arm of the maze 
for each day. The same spatial cues used in the Morris water maze were provided on the 
walls surrounding the RAWM task throughout testing. Each day of RAWM testing 
consisted of four acquisition trials and one memory retention trial. RAWM testing was 
conducted over nine successive days. For each acquisition trial, a mouse was placed in 
the water at the entrance of a novel start arm of the maze for that day facing the central 
swimming area. This start arm was never the same arm that contained the submerged 
escape platform, and the start arm sequences and goal arm location were semi-randomly 
selected each day. The mouse was then allowed to navigate the maze for 60 seconds. 
During this 60 s, if the mouse chose the wrong arm (that did not contain the escape 
platform) it was gently guided back to the start arm to renew navigating the maze and an 
error was recorded. If a mouse fails to select an arm within 20 seconds, it was gently 
guided back to the start arm and an error was recorded. If the animal failed to find the 
platform at the end of 60 s, it was gently guided to it. Once locating the platform, the 
mice were allowed a 30 s rest period. The latency to escape the maze and the number of 
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wrong arm choices were recorded over all four successive acquisition trials. Upon 
completion of the fourth acquisition trial, the mice were returned to their home cage for a 
30 minute interval before being returned to the pool for the fifth and final trial of the day, 
the memory retention trial. The last trial of the four successive trials (trial 4, T4) and the 
30-minute delayed retention trial (trial 5, T5) are considered measures of working 
memory. Any mouse that did not make at least 3 choices during a trial and were unable to 
locate the escape platform had a penalty assessed for that trial. This penalty was 
calculated by averaging trial one errors for the first three days of testing for animals 
which could not find the escape platform but made more than three arm choices during 
those trials. For this study, the penalty error assessed was 7.1. 
Brain Collection 
 Immediately following completion of behavioral testing, all mice were 
anesthetized with Nembutal (1mg/10 gm body weight), then pericardially perfused with 
0.9% saline. Brains were then removed and split into halves by a single mid-saggital cut. 
The left hemisphere was fixed in 4% paraformaldehyde for 24 hours at 4°C, followed by 
graded sucrose solutions (10, 20, and 30% (w/v) sucrose in 0.1 x Sorenson’s phosphate 
buffer). The right hemisphere was dissected out into the following areas: cerebellum, 
anterior and posterior cortex, striatum, and hippocampus. These areas were immediately 
frozen on dry ice and stored at -80°C. For half the animals in each group, the right frontal 
cortex, striatum, and hippocampus were used to measure the densities of adenosine 
receptors.  For the remaining half of animals in each group, the right hippocampus was 
used to determine levels of soluble/insoluble Αβ and combined right frontal + posterior 
cortex was used for analysis of α- and β-carboxyl terminal fragments. 
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Analysis of β- and α- CTFs (carboxyl terminal fragments) 
  This procedure was performed by Dr. Jun Tan and Kavon Rezai-zadeh. Frontal 
and posterior cortices were  thawed, combined, and placed in ice-cold lysis buffer (20 
mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL 
leupeptin) with 1 mM PMSF.  Brain tissues were then sonicated on ice for approximately 
3 mins, cooled on ice for 15 mins, and then centrifuged at 15,000 rpm for 15 mins. 
Following homogenization, aliquots corresponding to 50 µg of total protein were 
electrophoretically separated using 16.5% Tris-tricine gels.  Electrophoresed proteins 
were then transferred to PVDF membranes (Bio-Rad), washed in dH2O, and blocked for 
1 hr at room temperature in Tris-buffered saline (TBS; Bio-Rad) containing 5% (w/v) 
non-fat dry milk.  After blocking, membranes were hybridized for 1 hr at room 
temperature with primary antibody [APP-carboxyl-terminal antibody 369(1:1000)].  
Membranes were then washed 3 times for 5 min each in dH2O and incubated for 1 hr at 
room temperature with the appropriate HRP-conjugated secondary antibody (1:1,000, 
Pierce Biotechnology, Inc. Rockford, Illinois).  All antibodies were diluted in TBS 
containing 5% (w/v) non-fat dry milk.  Blots were developed using the luminol reagent 
(Pierce Biotechnology). Blot intensities were analyzed qualitatively and assessed a ratio 
of 2:1 or 1:1 depending on their intensities in relation to each other (β-CTF vs. α-CTF). 
Adenosine Receptor Densities (Completed by Dr. Edward Jackson) 
Western Blotting.   The tissues were placed in eppendorf tubes with 0.1mml SDS 
buffer (50mMTris, ph 7.0, 2% SDS, 10% glycerol) containing protease inhibitors 
(2µg/ml antipain, 1 ug/ml aprotinin, 2 ug/ml leupeptin, 1 mg/ml phenylmethylsulfonyl 
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fluoride) and homogenized with a small plastic pestle in ice. The homogenate was 
centrifuged at 12,000 rpm at 4’C for 10 min, and the supernatant was recovered. Protein 
in the supernatant was terminated by the copper bicinchoninic acid method. Laemmli 
buffer was added to samples, after which they were placed in boiling water for 5 min and 
then chilled immediately on ice. 15 µg protein/well samples were loaded onto a 7.5-10% 
acrylamide gel and subjected to SDS PAGE using the Bio-Rad minigel system.  Proteins 
were then electroblotted onto a polyvinylidine difluride membrane. The membrane was 
blocked with 5% milk for 1h and incubated at 4’C overnight with the first antibody (anti-
A1 1:1000 diluted in PBS containing 0.5% Tween 20; anti-A2a 1:1000 diluted in PBS 
containing 0.5% Tween 20, antibodies were from Santa Cruz). After three washes with 
PBS containing 0.5% Tween 20, the membrane was incubated at room temperature for 1h 
with HSP-conjugated secondary antibody (Amersham) at 1:10,000 dilution. The 
membrane was exposed to film and the signals were detected by a supersignal substrate 
kit (Pierce). 
RT-PCR.   Total RNA was isolated using Trizol reagent solution (GIBCO). By 
using the primer sequences listed in Table 2, 0.5 µg RNA was reverse transcribed and 
amplified using a Titanium One-Step RT-PCR Kit (Clontech). Each PCR cycle (a total of 
30 cycles for A1 and 32 cycles for A2a) consisted of denaturing at 94°C for 30 s, 
annealing at 64°C for 30 s, and extension at 72°C for 60 s. The products were separated 
on a 1% agarose gel with EB staining and the signal was detected by UV.  
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Table 2.   Mouse adenosine receptor PCR primers and cDNA sizes 
Receptor  Accession No.   Primer     Nucleotides        Sequence 5’-3’                    Product 
Size 
A1          NM_009629     Forward      659          TAGGGCAACGCCTTTGGGAC       849 
                                          Reverse     1507         ATGGGTGTCAGGCCTACCAC 
A2A       NM_009630     Forward      177          GCCATCACCATCAGCACTGG       734 
                                          Reverse     910           TCAGGACGTGGGTTCGGATG 
 
The band densities were quantitatively measured using Scion-image software. 
Background signals were obtained in each lane and subtracted from the band densities to 
correct for the background signal. 
Effects of Caffeine Administration in Aged APPsw Mice 
General Protocol 
 At 17 months of age, 8 APPsw mice and 3 non-transgenic (NT) littermates were 
randomly selected to determine the effect of caffeine administration on both extracellular 
brain levels of adenosine and soluble/insoluble brain Aβ levels.  
 Four APPsw group-housed mice were given ad libum access to water with 0.3 
mg/mL caffeine (Sigma) dissolved in it, as per the long-term study. Four APPsw mice and 
three NT group-housed mice were not administered caffeine in their drinking water and 
thus served as controls. Mice were kept under these conditions for 18 days, at which 
point they were euthanized (Fig. 5) and brains were removed for quantification of 
extracellular brain adenosine levels, soluble/insoluble Aβ levels, γ-secretase activity, and 
S-adenosyl methionine (SAM) levels. The weights of the animals were monitored 
throughout this study to ensure no significant weight reductions occurred. 
Study Timeline 
Oral Administration 
of Caffeine 
Animals 
Sacrificed 
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Fig. 5. General protocol time line for caffeine administration in aged mice. 
Brain Collection 
 Immediately following caffeine treatment, all mice were anesthetized with 
Nembutal (1mg/10 gm body weight). Each mouse’s skullcap was surgically removed and 
the brain was quickly excised and split into halves by a single mid-saggital cut. The left 
hemisphere was rapidly snap-frozen in liquid nitrogen and reserved for measurement of 
extracellular brain adenosine levels through HPLC. This technique was done quickly to 
protect the tissue from ischemic conditions which would disrupt any adenosine 
measurements. The right hemisphere was dissected out into the following areas: 
cerebellum, anterior and posterior cortex, striatum, and hippocampus. These areas were 
immediately frozen in dry ice and stored at -80°C. Later, the hippocampus was used to 
measure the levels of soluble and insoluble Aβ through ELISA. Combined anterior and 
posterior cortices were later analyzed for both γ-secretase activity and S-adenosyl 
methionine levels. 
 
18 17 
Months 
17.5 
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Measurement of Brain Adenosine Levels (Completed by Dr. Edward Jackson) 
 Sample Preparation.   Half brains were weighed (50-60 mg) and washed with 
500µL cold phosphate-buffer saline (PBS). Tissue was transferred to a centrifuge tube 
containing 500µL water and then boiled for four minutes to inactivate adenosine 
deaminase (and any other enzymes present in the sample). The tissue was then 
homogenized in a power homogenizer and centrifuged at 14,000 rpm for five minutes. 
The supernatant was drawn off and centrifuged a second time. The resulting supernatant 
was loaded onto centrifugal filter devices (Biomax-30, Millipore) and filtered to remove 
proteins. The filtrate was diluted 1:200 in water and internal standard (adenine 9-β-D 
arabinofuranoside) was added to a final concentration of 10 pg/µL. The standard curve 
was created in water and the samples were analyzed with an LCMS assay. 
Mass Spectrometry.    The assay was developed using a Thermofinnigan HPLC 
system coupled to a Thermofinnigan LCQ Duo ion trap mass spectrometer equipped with 
an electrospray ionization source (ESI).  The mass spectrometer was operated in the ESI 
positive ion mode. The analytes were monitored using single ion monitoring; for 
adenosine and adenine 9-β-D arabinofuranoside (internal standard), the m/z was 268.  
Measurement of γ-Secretase Activity (Collaboration with Kavon Rezai-zadeh) 
 Brain samples consisting of combined frontal and posterior cortices were placed 
in ice-cold lysis buffer (20 mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM 
Na3VO4, 1 µg/mL leupeptin).  Brain tissues were then sonicated on ice for approximately 
3 mins, cooled on ice for 15 mins, and then centrifuged at 15,000 rpm for 15 mins.  No 
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PMSF was added to these samples as it may disrupt the activity of γ-secretase. Cell 
lysates from these samples were then analyzed for γ-secretase activity using a γ-secretase 
kit provided by R&D Systems, Inc.. Following the manufacturer’s protocol, a secretase-
specific peptide conjugated to reporter molecules EDANS and DABCYL was added to 
each cell lysate. Cleavage of this peptide by the γ-secretase present from each cell lysate 
results in a fluorescent signal that is proportional to the level of secretase enzymatic 
activity. Fluorescent signals were detected using a fluoromentric reader. Protein 
concentrations were quantified to ensure equal protein levels were present in each 
sample. 
SAM (S-adenosyl-methionine) Quantification (Collaboration with Kavon Rezai-zadeh) 
 The same cortical homogenates used for γ-secretase activity were also used for 
SAM quantification.  SAM was quantified in these samples using a Bridge-It S-
Adenosyl-Methionine (SAM) Fluorescence Assay provided by Mediomics, LLC.  
Following the manufacturer’s protocol, 10µl of each sample were added to a 
polypropylene Eppendorf tube. 90µl of SAM assay solution was added to each sample 
and vortexed for ~1 second.  Then, 90 µl of the resultant mixture from each sample was 
loaded in a black microplate, covered and incubated in the dark for 30 minutes. The 
fluorescent intensity was then measured using a fluorescent microplate reader (settings: 
excitation ~485 nm; emission ~665 nm). By using the standard curve generated by the 
fluorescence of known SAM levels, the concentration of SAM in unknown samples was 
calculated by its fluorescent intensity. Protein concentrations were quantified to ensure 
equal protein levels were present in each sample. 
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Determination of Soluble/Insoluble Aβ Levels  
Tissue Homogenizing/Extraction.   To determine the levels of both 
soluble/insoluble Aβ(1-40) and Aβ(1-42), the hippocampi from mice in each group (6 
Tg+caff, 6 Tg+, 1 NT from Study A and 3 Tg+caff, 3 Tg+, 1 NT from Study B) were 
homogenized in tissue homogenization buffer (THB) (250mM sucrose, 20mM tris-HCl, 
1mM EDTA, 1 mM EGTA, and protease inhibitor). 0.4% diethylamine (DEA; in 100 
mM NaCl) solution was added to each homogenate and each sample was then centrifuged 
at 100,000 x g for one hour. The supernatant from each sample was drawn off and stored 
at -80°C for later quantification of soluble Aβ levels. Formic acid (FA) was then added to 
the remaining pellet and samples were sonicated for one minute. Following sonification, 
samples were spun down at 100,000 x g for one hour. The intermediate phase was drawn 
off, and added to a FA neutralization solution. These FA-extracted solutions were 
designated for quantifying insoluble Aβ levels and stored at -80°C. 
Αβ (1-40) and (1-42) ELISA.   Sandwich ELISA kits for both Aβ (1-40) and (1-
42) were utilized (Signet laboratories). All extracts were thawed and appropriately diluted 
to ensure results within the standard curve for each kit. Plates were coated with capture 
antibodies specific to the amino-terminus for either the Aβ peptide (1-40) or (1-42), 
depending on which kit was being used. Before loading the samples, each plate was 
washed three times in a wash diluent. The standard curve (consisting of samples with 
known amounts of Αβ peptide) and each brain sample extract were run in duplicate and 
averaged to obtain the most accurate results. After loading the samples, the plate was 
incubated at 4°C overnight and was washed three times the next day to remove unbound 
peptide. A primary antibody was then added that binds to the carboxy-terminus of the 
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peptide and allowed to incubate for two hours. After washing, a secondary antibody 
conjugated to horseradish peroxidase was added to bind to the primary antibody and 
allowed to incubate for another two hours. The plate was again washed and an O-
phenylenediamine (OPD)-substrate was added to each well that visualizes the bound Aβ 
peptide by reacting with horseradish peroxidase. This reaction occurred for 45 minutes, at 
which point a stop solution was added and the plate was read at an absorbance of 490 nm. 
The optical density (OD) for each sample was measured and compared to the OD of the 
standard curve, allowing for the quantification of bound Aβ (either 1-40 or 1-42 
depending on which kit was used) in each well. 
Statistical Analysis 
Behavior.   Standard one-way ANOVAs were performed using Statistica software 
to determine inter-group behavioral comparisons between APP mice, caffeine-treated 
APP mice, and NT mice in the open-field, balance beam, Y-maze, elevated plus-maze, 
Morris water maze acquisition and probe trial, circular platform, platform recognition, 
and radial arm water maze (RAWM) tasks. Post-hoc pair-by-pair differences between 
groups (planned comparisons) were later determined by the Fisher LSD test. Two-way 
repeated measure ANOVAs were also performed to elucidate any behavioral differences 
in groups in the multi-day tasks across days (platform recognition) and blocks (3-day 
blocks for RAWM or 2-day blocks for Morris water maze acquisition). Mann-Whitney 
U-tests for non-parametric data were performed to compare performance of mice in the 
string agility task. RAWM swim speed was calculated by averaging overall T4+T5 
latency and dividing by the average of overall T4+T5 errors. Any animals that were 
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consistently unable to complete any task (e.g., floaters, circlers) were eliminated from 
statistical analysis.  
Pathology.   Group comparisons for insoluble/soluble Aβ, adenosine receptor 
measurements, secretase activity, SAM levels, and brain extracellular adenosine levels 
were done by standard one-way ANOVAs. After ANOVA analysis, post-hoc pair-by-pair 
differences between groups were analyzed with the Fisher LSD test. Correlation analysis 
was also performed using Systat software to elucidate any potential relationships between 
the behavioral, Aβ pathology, and brain adenosine measures. 
Factor/Discriminant Factor Analysis.   Factor analysis (FA) was performed using 
Systat software to group all behavioral measures into common factors. This allows for the 
relationship between individual behavioral measures to be determined, and also might 
indicate potential performance in a task based on previous performance in another task. 
This FA was performed using all 19 behavioral measures from all groups (NT, APPsw, 
and APPsw+Caffeine) in this study. 
 To investigate if a relationship exists between behavioral and Aβ pathological 
measures, correlation analysis was performed using Systat software. Correlation analyses 
were performed between all 19 behavioral measures and all four Aβ measures. 
Correlation analyses were also performed between all 19 behavioral measures to 
determine if any inter-task relationships existed. Finally, correlation analysis was also 
performed to determine the relationship between extracellular brain adenosine levels and 
the four Aβ measures. 
 Additionally, discriminant factor analysis (DFA) was run using Systat software 
with two different DFA methods (direct entry and stepwise-forward) using all 19 
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behavioral measures and also only the 8 cognitive-based measures that loaded from 
Factor 1. These DFA’s determined if the three groups of mice were behaviorally distinct 
from one another. The direct entry method used all 19 behavioral measures, or the 8 
measures from Factor 1 of FA, while the stepwise-forward method started with 19 or 8 
measures, respectively, but selected from these measures based on their variance to best 
differentiate between the three groups. 
 
 
 
VI. Results 
Weight Analysis.   Throughout the study, mice in all three groups were weighed 
every two weeks to ensure no significant differences occurred from the four month 
caffeine treatment. Before the start of the caffeine treatment, there were no group 
differences in weight between the transgenic and non-transgenic mice. Additionally, there 
were no group differences between the NT, Tg, and Tg+Caff mice at the end of 
behavioral testing when the animals were euthanized. Repeated measures analysis 
revealed no group by time interaction [F(13,260)=0.66; p=0.89], indicating NT, Tg, and 
Tg+Caff mice all gained weight at a similar rate during the entire four month period of 
treatment.  
Behavior- Sensorimotor Evaluation 
 Open Field and Y-Maze Entries.   Tg mice exhibited increased open field activity 
(Fig. 6a) when compared to NT controls (p<0.05), while activity of Tg+Caff mice was 
not differ from NT mice at 8 months of age. Furthermore, both Tg and Tg+Caff mice 
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made significantly more total arm choices in the Y-maze task (Fig. 8a), another measure 
for activity/exploration, when compared to NT mice (p<0.02 for both groups). 
 Balance Beam.   In balance beam testing, there were no group differences 
between the mice (Fig. 6b), indicating that all mice had similar balance ability and intact 
general motor function. 
 String Agility.   In the string agility test (Fig. 6c), the Tg+Caff mice were less 
agile than the Tg and NT mice (p<0.05), although this difference was simply because less 
Tg+Caff mice escaped the string (score of 5) than the other two groups. As Tg+Caff mice 
averaged a ranking of 4 in this task, they managed to cling to the string with all limbs for 
the full 60 seconds and did not fall. Therefore, the difference does not imply a motor 
impairment in Tg+Caff mice.  The treatment-related impairment was task specific and, 
moreover, did not influence performance in the cognitive-based tasks (see correlation 
analysis). 
Elevated Plus-Maze Anxiety.   There were no group differences in open and 
closed arm entries (Fig. 7b and c). Tg mice, but not Tg+Caff mice, spent more time in 
open arms when compared to NT mice (p<0.05; Fig. 7a). 
Behavior- Cognitive Evaluation 
 Y-Maze Alternation.   In Y-maze testing for spontaneous alternation behavior, 
there were no group differences in percent alternation (Fig. 8b). Tg mice were 
unimpaired in this task, thus any protective effect from the long-term administration of 
caffeine was not possible. 
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Figure 6. Open field, balance beam, and string agility performance.   Tg mice 
showed increased activity in the open field task. Tg+Caff mice had decreased 
performance in the string agility task, but did not have any general motor impairment. * = 
significantly different from NT group at p<0.05, ** = significantly different from both 
other groups at p<0.05. 
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Figure 7. Elevated plus-maze performance.   Tg mice spent significantly more time in 
the open arms than NT mice, while Tg+Caff mice were no different than NT mice. * =  
significantly different from NT group at p<0.05. 
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Figure 8. Y-maze performance.   Both Tg and Tg+Caff mice had significantly more 
arm entries than NT mice. * = significantly different from NT group at p<0.02. 
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 Morris water maze acquisition.   Escape latency data from this task were divided 
into five 2-day blocks. There was no overall group effect across all five blocks 
[F(2,50)=1.69; p=0.19] (Fig. 9).  However, a strong group by block interaction was 
evident [F(8,200)=3.51; p=0.0008], which was clearly due to the inability of Tg mice to 
improve acquisitional performance after the second block of testing.  Post hoc analysis of 
individual blocks revealed NT and Tg+Caff mice showed a strong learning effect in the 
last two blocks acquisition, resulting in significantly faster escape latencies when 
compared to Tg mice (Fig. 9).  Not surprisingly, Tg escape latencies on the last day of 
testing were also significantly higher than NT and Tg+Caff escape latencies (p<0.5 and 
p<0.02, respectively.  Thus, the long-term administration of caffeine protected against 
Morris maze acquisitional impairments that would otherwise be present in APPsw mice at 
this age. 
 Results from the Morris maze probe trial are consistent with the protective effect 
of caffeine treatment in APPsw mice during acquisition (Fig. 10).  Tg mice showed no 
quadrant preference during this spatial memory retention phase of testing.  By contrast, 
Tg+Caff mice showed an exclusive preference for the quadrant formerly containing the 
submerged platform (Q2) and spent significantly more time in this quadrant than  
Tg mice (p<0.025).  NT mice showed only a partial preference for Q2, although their 
percent time spent in Q2 was not statistically different from that of Tg+Caff mice.  
Tg+Caff mice also made significantly more annulus crossings than Tg mice (p<0.005; 
Fig. 10), giving further support for a protective effect of caffeine treatment in spatial 
memory retention.
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Figure 9. Morris water maze acquisition latencies.   The 10 days of acquisition, as 
measured by latency to find a submerged platform, are presented in five 2-day blocks. Tg 
mice were significantly impaired in spatial reference learning in blocks 4 and 5, while 
Tg+Caff mice performed no different than NT mice. † = Tg mice had significantly higher 
escape latencies than both other groups at p<0.05 or higher level of significance. 
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Figure 10. Probe trial testing for reference memory retention in the Morris water 
maze.    Tg+Caff mice showed an exclusive preference for the quadrant formerly 
containing the submerged platform (Q2). This preference is also indicated by the 
significantly higher number of annulus crossings made by Tg+Caff mice when compared 
to Tg mice. * = significantly greater than all other quadrants at p<0.01 and significantly 
greater than Q2 for Tg group at p<0.025. ** = significantly different from Tg mice at 
P<0.005. 
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 Circular Platform.   In this task of reference learning/memory, there was an 
overall groups effect over all eight days of testing [F(2,51)=7.66; P=0.001].  Post hoc 
analysis indicated that Tg mice had significantly higher escape latencies overall 
compared with NT and Tg+Caff mice (p<0.005; Fig. 11). Additionally, Tg escape 
latencies were significantly higher than NT and Tg+Caff escape latencies on the last day 
of testing (P<0.025 and P<0.001, respectively).  Very similar group differences were 
observed when the number of errors was analyzed (data not shown).  For all animals, 
there was an overall training (days) effect [F(7,357)=37.33; p<0.00001], indicating that 
all animals collectively improved their performance across days despite the impaired 
performance of Tg mice.  Thus, the otherwise certain impairment of APPsw mice in the 
circular platform task, evident in both their escape latencies and error making, was 
prevented by the long-term administration of caffeine. 
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Figure 11. Circular platform performance.   Tg mice were significantly slower in 
locating the escape hole over the eight days of circular platform testing, while Tg+Caff 
mice performed similarly to NT mice. † = Tg mice significantly higher escape latencies 
than both other groups at p<0.01 or higher level of significance. 
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 Platform Recognition.   In platform recognition testing, an overall groups effect 
was present [F(2,49)=7.44; p<0.002], with post hoc analysis revealing that Tg mice had 
significantly higher escape latencies than NT mice (P<0.0005; Fig. 12).  By contrast, 
Tg+Caff mice performed at the same level as NT mice and nearly had lower overall 
escape latencies compared to Tg mice (p=0.065). The benefits of caffeine administration 
were evident even on the second day of testing and were profound by the last two days of 
testing (Fig. 12) in that Tg+Caff mice performed identically to NT mice and significantly 
better than Tg mice on both of those final days.  A strong group by day interaction was 
present [F(6,147)=4.14; p<0.001] due to the poor performance of the Tg group relative to 
the other two groups.  The apparent difficulties that Tg mice have in switching between 
the spatial (cued) strategy used in Morris water maze to a search/recognition strategy in 
the platform recognition task are reflected in their high escape latencies.  In sharp 
contrast, the long-term administration of caffeine protected against this “strategy 
switching” impairment. 
 RAWM.   For RAWM statistical analysis, data was evaluated across three 3-day 
blocks for T1 (semi-randomized initial trial), T4 (final acquisition trial), and T5 (delayed 
retention trial). The beneficial effects of caffeine on working memory were immediately 
evident in block 1 of testing (Fig. 13).  Tg+Caff mice were similar in performance to NT 
controls and already better than Tg mice (p<0.05) during T4, while Tg mice were 
impaired during both T4 (p<0.0001) and T5 (p<0.00001).  In blocks 2 and 3 of testing, 
Tg mice had significantly higher escape latencies during working memory trials T4 and  
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Figure 12. Platform recognition performance over four days of testing.   By the third 
and fourth day of testing, performance of Tg+Caff mice was identical to NT mice and 
much better than Tg controls.  * = Tg and Tg+Caff mice significantly worse than NT 
mice at p<0.05, † = Tg mice significantly worse than both NT and Tg+Caff mice at 
P<0.05 or higher level of significance.  
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Figure 13. RAWM performance over three 3-day blocks.   During the first block of 
testing, Tg mice had significantly slower escape latencies versus NT mice during T4 and 
T5 (the trials indicative of working memory) while Tg+Caff mice were not different from 
NT during T4. In the final two blocks of RAWM, Tg performance was significantly 
higher in T4 and T5 than both NT and Tg+Caff mice, the later two groups being near 
identical in performance.  † = Tg mice significantly worse than both NT and Tg+Caff 
mice at p<0.05 or higher level of significance. * = Tg and Tg+Caff mice significantly 
different from NT mice at P<0.0001,  
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 T5 compared to NT and Tg+Caff mice (P<0.05 or higher levels of significance). 
Tg+Caff mice, by contrast, were identical in working memory performance in 
comparison to NT mice.  A strong group by block interaction was present for T5  
 [F(4,98)=5.66; p<0.0005], which was clearly due to the much poorer T5 performance of 
Tg mice compared to the other two groups.  The consistent impairment of untreated 
APPsw mice in T4 and T5 of RAWM testing indicate impaired working memory in these 
mice, whereas the long-term administration of caffeine to APPsw mice offers protection 
against working memory impairment. 
The complete protection of working memory provided by caffeine is also 
manifest in overall performance across all three blocks (Fig. 14).  In overall T1 
performance across all three blocks, Tg mice had significantly slower escape latencies in 
comparison to NT mice (P<0.025) while Tg+Caff mice were nearly different from NT 
mice (p=0.051).  Escape latencies in overall T4 and T5 performance showed that Tg mice 
were substantially impaired when compared to NT mice (p<0.00001), while Tg+Caff 
mice were not different from NT mice and significantly better than Tg mice (p<0.005).  
Additional support for impaired RAWM working memory in Tg mice was evident in by 
their increased number of overall T4 and T5 errors made in comparison to NT controls 
(p<0.0001 for both; data not shown).  This impairment was also prevented by the long-
term administration of caffeine, as Tg+Caff mice performed similarly to NT mice in 
making significantly lower numbers of overall T4 and T5 errors compared to Tg mice 
(p<0.0001 and p<0.005, respectively).  There were no group differences in swim speed 
present in RAWM testing, indicated by the number of seconds taken per arm choice 
(latency/error ratio) for T4 and T5 combined. 
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Figure 14. Overall RAWM performance.  In working memory trials T4 and T5, 
Tg+Caff mice performed identical to NT controls and were significantly better than Tg 
control mice, indicating that the long-term administration of caffeine granted complete 
protection against working memory impairment in RAWM testing. * = Tg mice 
significantly higher latency than NT mice at P<0.025, † = Tg mice significantly worse 
than both NT and Tg+Caff mice at P<0.005 or higher level of significance. 
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Multi-metric Statistical Analysis   
 Factor Analysis.   Factor analysis of behavioral measures was performed to 
determine the underlying relationships between all of these measures (Table 3). FA 
involving all 19 behavioral measures resulted in 13 of those measures loading on four 
principal factors, which accounted for 61.2% of the total variance (a measure was 
considered “significant” for loading on a factor if its component loading value exceeded 
0.600 for that factor). All measures for RAWM, Morris maze acquisition, and platform 
recognition loaded heavily in factor 1, thus this factor was considered the primary 
cognition-based factor. The measures for activity and/or having an activity component 
(open field, Y-maze entries, and circular platform errors) loaded into factor 2, while 
circular platform latency loaded separately into factor 4 and balance beam loaded 
separately into factor 5. No tasks loaded into factor 3. 
 Correlation Analysis.   Correlation analyses were performed using all 19 
behavioral measures and including all mice (Tg and NT). There were no correlations 
between the string agility task and any of the cognitive tasks. Additionally, correlation 
analysis revealed that the amount of time mice spent in the open arm of the elevated plus 
maze correlated with an increased latency in multiple tasks (Morris maze, circular 
platform, platform recognition, and RAWM). This may indicate that mice with decreased 
anxiety are less motivated to escape certain tasks.  As expected, there were numerous 
inter-task correlations between measures in the three water-based.  For measures taken 
from the same task, strong intra-task correlations were also evident, particularly for 
RAWM and Morris maze tasks. 
Table  3. Factor loadings of behavioral measures
Factor All 19 behavioral measures
1 (32.61)
RM-T4-Fin
RM-T4
RM-T5-Fin
RM-T5
PR-Fin
PR-Avg
WM-Fin
WM-Avg
2 (13.97)
OF
CP-Err
YM-Ent
3 (10.10)
N/A
4 (8.247)
CP-Lat
5 (6.37)
BB  
 
Numbers in bold type indicate percent of total variance explained by a given factor.  
Abbreviations: BB, balance beam; CP-Err, circular platform overall errors; CP-Lat, 
circular platform overall latency; OF, open field lines crossed; PR-Avg, Platform 
recognition overall average; PR-Fin, Platform recognition final day average; RM-T4, 
radial arm water maze latency overall T4; RM-T5, radial arm water maze latency overall 
T5; RM-T4-Fin, radial arm water maze latency last block T4; RM-T5-Fin, radial arm 
water maze latency last block T5; WM-Avg, water maze latency overall average; WM-
Fin, water maze latency last day; YM-Ent, Y-maze entries.  
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 Discriminant Function Analysis.   DFA was utilized to determine if multiple 
behavioral measures could distinguish the three groups (NT, Tg, Tg+Caff) from one 
another (Table 4). The “direct entry” DFA method (which includes all behavioral 
measures) and the “stepwise forward” DFA method (which selects behavioral measures 
from the total number evaluated based on their contribution to the variance) were used in 
this analysis. Direct entry DFA, using all 19 behavioral measures, was very effective in 
completely discriminating between all three groups (rank order of performance was NT > 
Tg+Caff > Tg). Additionally, the stepwise forward DFA (using all 19 behavioral 
measures) was also very effective in completely discriminating between all three groups 
(P<0.0001). For the stepwise forward DFA, five behavioral measures were retained as 
providing maximal discriminability: three cognitive-based measures (RAWM overall T4  
latency, Morris maze retention, and circular platform overall latency) and two 
sensorimotor measures (Y-maze entries and elevated platform time in open arms). 
Additional DFAs were performed using only the eight cognitive-based measures 
that loaded on factor 1 in FA (see Table 3). Both direct entry and stepwise forward DFAs 
(using these eight cognitive-based measures) were able to completely discriminate 
between all three groups.  Six measures (three from RAWM, two from platform 
recognition, and one from Morris maze) providing the maximal discrimination between 
NT, Tg, and Tg+Caff groups. Canonical plots of both the 19 and 8 measure stepwise 
forward DFAs are shown in Fig. 15.  DFA’s involving all 19 behavioral measures was 
slightly better at correctly classifying individual animals into their treatment/genotypic 
group (84-90% correct) compared to DFA’s involving the 8 cognitive measures in factor 
1 (75-79%). 
Table  4. Summary of discriminant function analysesa
Measures Direct Entry Method Stepwise-forward method
Significance % Correct Significance % Correct Measures 
Retained
All 19 P<0.0001 90% P<0.0001 84% RM-T4
WM-Ret
CP-Lat
YM-Ent
EP-TO
Factor 1 P<0.0001 79% P<0.0001 75% RM-T4
 (Eight cognitive measures) RM-T5
RM-T4-Fin
WM-Avg
PR-Fin
PR-Avg
a P-values are from Wilks's λ. Post hoc analysis revealed complete discrimination between groups.
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Fig. 15.   Canonical score plots of stepwise-forward DFAs used to compare the 
“overall” cognitive performance of the three mouse groups.   Each symbol represents 
the cognitive performance of one animal graphed from the two linear functions derived in 
the DFA. In both DFAs, all three groups could be completely distinguished from one 
another. 
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Neuropathologic/Neurochemical Measures: Study A 
Adenosine Receptor Measures.   Adenosine A1 and A2A receptor densities from 
striatum, hippocampus, and frontal cortex from mice in Study A were analyzed using 
western blotting (Fig. 16). No group differences in adenosine A1 receptors were seen in 
striatum or hippocampus, but Tg and Tg+Caff mice both had significantly higher levels 
of A1 receptors in the frontal cortex compared to NT mice (p<0.05). Furthermore, no 
group differences were seen in adenosine A2A receptors in striatum or frontal cortex, but 
Tg mice had significantly higher levels of A2A receptors in the hippocampus versus NT 
mice (p<0.05). 
The mRNA levels for A1 and A2A adenosine receptors were also analyzed in the 
corresponding areas using RT-PCR. This evaluation revealed no significant group 
differences in A1 receptor mRNA expression in striatum, hippocampus, or frontal cortex. 
A2A receptor mRNA expression was below detectable levels in frontal cortex and 
hippocampus, while in the striatum no group differences were qualitatively found in A2A 
receptor expression. 
 Αβ (1-40) and (1-42) Analysis.   Shortly following completion of behavioral 
testing in Study A at 9 months of age (and approximately 4 months into long-term 
caffeine administration), Aβ analysis by ELISA was performed on hippocampus tissues 
(Fig. 17). Long-term administration of caffeine resulted in significant reductions of both 
soluble Aβ1-40 (↓37%) and insoluble Aβ1-42 (↓32%). From this data, it is clear that the 
long-term administration of caffeine has an impact on brain Aβ production and/or 
clearance.
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Figure 16. Adenosine A1 and A2A receptor densities in the striatum, hippocampus, 
and frontal cortex (Study A).   The long-term administration of caffeine had no effect 
on A1 receptors in any areas of the brain examined, although a transgenic effect of 
increased A1 receptor density in the frontal cortex was observed. A further transgenic 
effect was seen with A2A receptor densities increased in hippocampus of Tg mice, with 
caffeine administration reducing this effect below significance. * = significantly different 
from NT at p<0.05. 
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Figure 17. Quantification of soluble/insoluble Aβ 1-40 and Aβ1-42 in hippocampus of 
behaviorally tested APPsw mice (Study A).   Caffeine-treated mice had significantly 
reduced soluble Aβ 1-40 and insoluble Aβ 1-42 levels when compared to untreated Tg mice. 
* Tg+Caff mice significantly lower versus Tg mice at p<0.05. 
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 Comparison of β- and α- CTFs.   To elucidate any changes in α- and/or β- 
secretase activity in combined frontal and posterior cortex tissue from behaviorally-tested 
mice of Study A, β-, and α-CTFs (carboxyl-terminal fragments) were analyzed by 
western blotting (Fig. 18). Qualitative assessment of the resultant gel revealed the same 
six Tg+Caff mice tested in the Aβ ELISA all had twice the β-CTF blot intensity of their 
α-CTF blot intensity (2 to 1 ratio), whereas the same six Tg control mice from the Αβ 
ELISA had more mixed blot intensities that leaned towards an even ratio between the two 
CTFs (1.33 to 1 ratio). Using a non-parametric Mann-Whitney test showed the difference 
between these group in CTF ratio was statistically significant (p<0.025). This data 
implies that caffeine has an impact on the amyloidogenic processing of APP. In NT mice, 
cortical levels of β− CTF’s were below the limits of detection. 
Neuropathologic/Neurochemical Measures: StudyB  
Αβ (1-40) and (1-42) Analysis.  An 18-day administration of caffeine to aged 17 
month old APPsw mice (Study B) resulted in a significant reduction of insoluble Aβ1-42 
(↓30%) in the hippocampus (Fig. 19). 
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Figure 18. Comparison of β-CTF to α- CTFs ratio in APPsw mice following long-
term caffeine administration (Study A).   Caffeine-treated mice had a significantly 
greater ratio compared to untreated Tg mice, consistent with a shift in amyloidogenic 
processing. * Tg+Caff mice significantly higher versus Tg mice at p<0.025. 
 
 96
 Tg Tg+Caff
pm
ol
/g
0
500
1000
1500
2000
2500
3000
Soluble Aβ1-40 
* 
Tg Tg+Caff
pm
ol
/g
0
5
10
15
20
25
30
35
Soluble Aβ1-42 
Tg Tg+Caff
pm
ol
/g
0
2000
4000
6000
8000
10000
12000
* 
Insoluble Aβ1-42 
Tg Tg+Caff
pm
ol
/g
0
10000
20000
30000
40000
50000
Insoluble Aβ1-40 
 
 
Figure 19. Quantification of soluble/insoluble Aβ 1-40 and 1-42 in hippocampus of aged 
APPsw mice (Study B).   Caffeine-treated mice had significantly reduced insoluble Aβ1-
42 levels compared to untreated Tg mice. * Tg+Caff mice significantly lower versus Tg 
mice at p<0.05. 
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Determination of γ-secretase Activity.   To more fully determine if a reduction in 
γ-secretase activity is involved in the reduction of amyloidogenic processing after 
caffeine administration, combined frontal and posterior cortex tissue from the mice in 
Study B were used to determine enzymatic activity of the γ-secretase class of proteases 
using a fluorometric reaction. There were no significant group differences between 
Tg+Caff and Tg mice (Fig. 20). However, γ−secretase activity in Tg+Caff mice was 
comparable to NT mice, with both of these groups having slightly reduced γ−secretase 
activity (?10%) when compared to untreated Tg mice.  It is possible that endogenous 
mouse secretase activity, unaffected by caffeine treatment, may be present and masking 
any actual reductions in harmful γ-secretase activity that may have been provided by 
caffeine treatment. Regardless, even slight reductions in γ-secretase activity might have 
beneficial effects on amyloidogenic processing, as evident by caffeine’s ability to reduce 
hippocampal Aβ levels in these same animals. 
 SAM Quantification.   To determine if long-term administration of caffeine has an 
impact on SAM (S-adenosyl-methionine) levels, combined frontal and posterior cortex 
tissue from the mice in Study B were used in a SAM fluorescence assay (Mediomics, 
LLC). There was no significant group difference between the Tg+Caff and Tg mice (Fig. 
21), yet SAM concentrations were 49% higher in the Tg+Caff mice (7.89 µM) than the 
Tg mice (5.30 µM). These results suggest that this analysis should be repeated, but next 
time using a greater number of samples and a more precise technique in the micromolar 
ranger.  
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Figure 20. Gamma- Secretase activity in cerebral cortex of APPsw mice following 
caffeine administration (Study B).   Caffeine treatment did not significantly affect γ-
secretase activity in our assay. Although it is possible that endogenous mouse secretase 
activity, unaffected by caffeine treatment, may be present and masking any actual 
reductions in harmful γ-secretase activity. 
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Figure 21. SAM (S-adenosyl-methionine) levels in cerebral cortex of APPsw mice 
following caffeine administration (Study B).   There were no significant group 
differences in SAM concentrations following the caffeine treatment. 
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 Extracellular Adenosine Analysis.   The left brain hemispheres from the aged 
APPsw mice used in Study B were analyzed for adenosine levels by mass spectrometry 
utilizing an ion-trap Finnegan LC-MS (Fig. 22). Interestingly, Tg mice had significantly 
reduced extracellular brain adenosine levels (↓27%) compared to age-matched NT 
(p<0.005).  By contrast, Tg+Caff mice had extracellular brain adenosine levels that were 
similar to NT mice and significantly higher than Tg mice (p<0.05 for Tg vs. Tg+Caff 
comparison). These results suggest Tg mice have pathologically lowered extracellular 
adenosine levels and caffeine administration restores those levels to normal. 
Correlation Analyses involving neurochemical/neuropathologic measures. 
Correlation analyses were performed between all 19 behavioral measures and the 
four measures of Aβ (e.g., soluble and insoluble Aβ1-40, Aβ1-42) for all Tg mice.  Other 
than significant correlations between circular platform impairment and both soluble and 
insoluble Aβ1-42, no significant correlations were found between the various forms of 
quantified Aβ and any of the other behavioral tasks. As expected from the data presented 
in Figures 16 and 20 involving aged Tg mice, a correlation was found between elevated 
adenosine levels and decreased levels of insoluble Aβ1-42 (r=0.856; p=0.03) within the 
hippocampus. 
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Figure 22. Quantification of extracellular brain adenosine levels in Aged Mice 
(Study B).   The administration of caffeine resulted in a significant elevation of 
extracellular adenosine levels in Tg+Caff mice to near that of NT mice, while untreated 
Tg mice had significantly reduced levels. **  = significantly lower than NT (p<0.005) 
and Tg+Caff mice (p<0.05). 
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VII. Discussion 
General Summary 
 In the present study, we determined behavioral and pathological changes in AD 
transgenic mice mediated by the long-term administration of caffeine to APPsw transgenic 
mice. The 4-month, daily administration of approximately 1.5 mg of caffeine to each 
mouse, equivalent to about five cups of coffee in humans, resulted in global protection 
against cognitive impairment. This behavioral protection was associated with reductions 
in both soluble and insoluble forms of Aβ in hippocampus, supporting other reports that 
cognitive impairment is Aβ dependent. Furthermore, an 18-day administration of caffeine 
to aged APPsw mice also led to reductions in Aβ, and normalized the otherwise decreased 
extracellular brain adenosine levels in untreated APPsw control mice. Importantly, results 
from this study establish a direct link between long-term caffeine usage and the 
SAM/SAH cycle, which when potentially disrupted in AD, has crucial implications in 
APP processing and specifically gamma-secretase activity. 
 The complete cognitive protection and reductions in AD-like pathology found in 
this study, together with the recent epidemiological study indicating a reduced risk of 
Alzheimer’s disease from moderate caffeine use (Maia and Mendonca, 2002), provide a 
compelling argument for future use of caffeine-based treatments in clinical trials to 
protect against AD. Given the already widespread use and acceptance of caffeine and the 
lack of serious side effects associated with long-term intake of caffeine in moderate 
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amounts, it would be advisable to include a moderate, sustained daily caffeine intake 
throughout life as a preventative against AD. 
 Behavioral Measures.   Caffeine administration protected Tg mice against 
cognitive impairment across tasks testing multiple cognitive domains (reference 
learning/memory, working memory, recognition/identification, strategy switching).  The 
global protection afforded by chronic caffeine administration was not only evident in 
every task wherein impairment was present in Tg mice, but also inclusive of all cognitive 
tasks, as discriminant function analysis clearly showed.  These wide-ranged cognitive 
benefits of caffeine administration did not involve significant side-effects on 
sensorimotor function that impacted cognitive performance because there were no 
correlations between sensorimotor function and cognitive performance.  A discussion of 
results from each task, in the order performed, in presented below. 
 No differences in Y-maze alternations were seen between the three groups, thus it 
is likely that the Y-maze task is not strict enough to detect any obvious abnormalities in 
basic mnemonic processing in 8-9 month old APPsw mice as previous studies have shown 
(Holcomb et al., 1999; King et al., 2002). Therefore, with no transgenic impairment 
present, the long-term caffeine administration to transgenic mice was unable to have any 
effect in this task. 
 Results from the acquisitional phase of Morris water maze revealed Tg mice had 
significant impairment in the fourth and fifth blocks, indicating that these mice have 
impaired spatial learning, as earlier studies have found (Hsiao et al., 1996; Westerman et 
al., 2002; Arendash et al., 2004). Further impairment was seen in Tg mice in the memory 
retention phase of this task, as these mice failed to show any preference for the quadrant 
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formerly containing the submerged escape platform. In contrast, Tg mice given caffeine 
had significantly quicker escape latencies during the acquisition phase of testing. 
Additionally, Tg+Caff mice showed an exclusive preference for the quadrant formerly 
containing the submerged escape platform, as indicated by their annulus crossings and 
time spent in this particular quadrant. These results indicate the long-term administration 
of caffeine protected APPsw mice against spatial/reference learning and memory 
impairment. 
 Tg mice showed additional impairment in the circular platform task, a behavioral 
task that also relies on spatial/reference learning and memory. In previous studies, Pompl 
et al. (1999) reported seven month old APPsw mice were impaired in circular platform 
performance when the escape hole’s location was changed (e.g., reversal learning).  In 
the present study, Tg mice were worse across all eight days of testing when compared to 
NT mice in the circular platform task.  By contrast, Tg+Caff mice performed identically 
to NT mice and substantially better than Tg controls in this task.  Additionally, Tg mice 
made significantly more errors than the other two groups on the last day of testing, 
further highlighting the cognitive impairment that the Tg group alone had and the 
protective affect of caffeine against this impairment.  It is noteworthy that the circular 
platform impairments evident in the present study’s APPsw mice were present without 
changing the escape whole’s location, as was the case for Pompl et al. (1999).  
 If performed after the Morris maze task, the platform recognition task relies 
heavily on the ability of mice to switch from the cued (spatial) strategy used in Morris 
water maze to a search/recognition strategy.  Difficulties doing this are associated with 
higher escape latencies. Previous behavioral characterizations reported APPsw mice of 
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similar age were impaired in this task (Hsiao et al., 1996; King et al., 2002; Arendash et 
al., 2004). Tg mice showed an overall impairment in platform recognition testing 
compared to NT controls, while Tg mice given caffeine performed equivalent to NT mice 
overall.  Moreover, on the last day of testing in this study, Tg mice had significantly 
higher escape latencies when compared to both NT and Tg+Caff mice.  Thus, chronic 
caffeine administration resulted in protection of strategy switching abilities in Tg mice. 
 As the most sensitive of all the cognitive-based behavioral tasks in our test 
battery, the RAWM task is proficient in elucidating working memory impairment in 
transgenic mice. An earlier study reported 15 month old APPsw mice were impaired in 
RAWM testing (Morgan et al., 2000), and Arendash et al. (2004) found recently that this 
impairment is evident as early as 6.5 months of age. Consistent with both of these prior 
studies, 8-9 month old Tg mice in the present study were impaired overall in both T4 and 
T5 of RAWM (the trials indicative of working memory), as evident by significantly 
higher escape latencies than NT mice.  As with all other cognitive tasks wherein the Tg 
group was impaired, Tg+Caff mice were protected against RAWM working memory 
impairment in performing significantly better than Tg controls and no different from NT 
mice.  The similar performance between NT and Tg+Caff mice in this sensitive task 
indicates that long-term caffeine treatment grants powerful protection against working 
memory impairment in these Alzheimer’s transgenic mice. 
 Consistent with earlier characterizations of this APPsw mouse model (Holcomb et 
al., 1999; King et al., 2002; Arendash et al., 2004; Leighty et al., 2004), no differences in 
overall sensorimotor performance that might indicate a gross motor dysfunction were 
seen in either Tg or Tg+Caff mice compared to NT controls.  The absence of differences 
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in the elevated plus maze between Tg and Tg+Caff mice shows that the long-term 
administration of caffeine does not result in any anxiety-based side effects that could 
explain the profound differences in cognitive performance between these two groups.  
These results are consistent with an earlier study reporting the lack of anxiolytic 
properties associated with long-term caffeine administration to rodents (Bhattacharya et 
al., 1997). 
In factor analysis, the loading of RAWM, platform recognition, and Morris water 
maze measures into factor 1 led this factor to be dubbed the primary cognitive-based 
factor.  Furthermore, both the direct entry and the step-wise forward methods of 
discriminant function analysis were able to completely discriminate between all three 
groups when using all 19 behavioral measures, as well as only the cognitively-based 
measures in factor 1. This indicates that the long-term administration of caffeine resulted 
in an overall protection of cognitive function across multiple behavioral measures, 
although the performance of NT mice across those multiple behavioral measures could 
still be distinguished from that of Tg+Caff mice.  Thus, multiple cognitive domains were 
protected by caffeine treatment in Tg mice. 
 The consistently poor performances of untreated APPsw transgenic mice in four of 
the five cognitive-based tasks used in the present study indicates that these particular 
mice exhibit widespread cognitive deficiencies that negatively impact spatial 
memory/learning, working memory, and recognition/identification in a manner similar to 
that of early to moderate Alzheimer’s disease in humans.  These impairments currently 
reported are consistent with an earlier behavioral characterization of APPsw mice 
involving the same transgenic colony (Arendash et al., 2004). Even more significant, the 
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long-term administration of caffeine to Tg mice, presumably started before these mice 
become cognitively impaired, resulted in a behavioral phenotype similar to that of NT 
mice. These results indicate caffeine’s potentially beneficial influences on the cognitive-
destabilizing processes apparent in Alzheimer’s disease are worth investigating in a 
clinical manner. 
 Previous studies investigating the behavioral effects of long-term caffeine 
administration to normal (wild type) rodents form a consensus that this treatment has no 
effects on cognition (Von Lubitz et al., 1993; Molinengo et al., 1994), although none of 
these studies lasted beyond 15 days. Therefore, it is sufficient to assume that the 
behavioral improvements seen in the caffeine-treated mice from the present study are a 
result of behavioral protection against over-expression of the mutated APP gene in APPsw 
mice, rather than a behavioral improvement resulting directly from caffeine’s immediate 
effects on cognition. Furthermore, the present study aimed to duplicate moderate dietary 
caffeine use in humans by placing mice on a truly long-term diet of caffeine 
administration lasting for four months and continuing throughout behavioral testing, thus 
establishing the mice are fully tolerant to caffeine and avoiding the potentially harmful 
effects of caffeine withdrawal. By ensuring the mice consumed a caffeine dose equivalent 
to approximately five cups of coffee in humans, the present study is the first of its kind to 
closely mimic the nature of human caffeine consumption that was found to be associated 
with a reduced risk of Alzheimer’s disease in a retrospective study (Maia and Mendonca, 
2002). 
 Neurochemical/Neuropathological Measures.  Long-term administration of 
caffeine resulted in no significant effects on A1 adenosine receptor densities in the 
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striatum, hippocampus, or frontal cortex of 9 month old, behaviorally-tested APPsw mice. 
Untreated APPsw mice did have significantly increased A2A receptors in the hippocampus, 
a finding that may indicate increased glial activation in this area as A2A receptors are 
generally only associated with glial or vascular cells when found within the hippocampus 
(Fiebach et al., 1996). Interestingly, caffeine administration did reduce these elevated 
hippocampal A2A receptor levels to a level that was not statistically different than NT 
mice, although the reduction was not great enough to result in a significant difference 
between Tg and Tg+Caff mice. No differences in A1 or A2A mRNA expression were seen 
following long-term caffeine administration in any of the groups in any of the brain areas 
examined, as other labs have reported in normal, wild type mice (Johansson et al., 1993; 
Shi and Daly, 1999). 
The long-term administration of caffeine resulted in significantly less soluble Αβ1-
40 and insoluble Aβ1-42 in the hippocampi of caffeine-treated APPsw mice when compared 
to the age-matched APPsw mice used in this study. Earlier characterizations of the APPsw 
mice have indicated their behavioral impairment was Aβ dependent, as age-related 
increases in amyloid levels (particularly the soluble isoforms) were found in the 
hippocampus and/or associate cortices that coincided with deterioration in cognitive tasks 
(Chen et al., 2000; Westerman et al., 2002). In the present study, reduced amyloid burden 
thus appears to be a primary cause for the lack of impairment in cognition-based tasks 
that the caffeine-treated APPsw mice exhibited. It is also noteworthy that the 18-day 
administration of caffeine to 17.5 month old APPsw mice also resulted in a significant 
reduction of insoluble Aβ1-42 in the hippocampus. This implies that caffeine 
administration has an effect on amyloid levels after they have reached substantial 
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amounts in aged APPsw mice, indicating long-term caffeine intake may have a treatment 
role as well as a preventative role in Alzheimer’s disease. 
The reductions in soluble Aβ1-40 and insoluble Aβ1-42 following caffeine treatment 
are likely associated with changes in amyloidogenic processing, as caffeine is too small 
molecularly to have an effect on binding to and clearing the much larger Aβ species. In 
cerebral cortical tissues from behaviorally-tested Tg mice, the increased ratio between β- 
and α-CTFs mediated by caffeine treatment thus suggests that caffeine has a direct 
impact on the secretases involved in amyloidogenic processing. Increases in β-CTFs 
could potentially be construed as a harmful precursor to Aβ generation that might result 
from increases in β-secretase or decreases in α-secretase activity (as the β-CTF results 
from β-secretase cleavage of APP and is the intermediate precursor that when cleaved by 
γ-secretase cleavage yields Aβ).  Yet in this case we theorize the increase in β-CTFs is a 
result of decreased γ-secretase activity. Less γ-mediated cleavage of β-CTFs in the 
caffeine-treated Tg mice would explain why they had a greater amount of β-CTF present 
relative to α-CTF and would also explain the decreases in Aβ found in these mice. 
When γ-secretase activity was assayed directly from cortical tissues of aged Tg 
mice after 18 days of caffeine administration, no statistically significant difference in γ-
secretase activity was seen between Tg and Tg+Caff mice. However, there is the 
possibility that a larger decrease in γ-secretase activity was masked by the presence of 
other endogenous mouse proteins that are unaffected by caffeine treatment yet share γ-
secretase’s preferred substrate used in our assay.  
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In the present study, aged APPsw mice had significantly reduced brain levels of 
extracellular adenosine, while the long-term (18 day) administration of caffeine restored 
adenosine levels in aged APPsw mice to those of NT mice. Although mice were give ad 
libum access to caffeine-treated water, it can generally be assumed that mice consume the 
most water during nighttime hours and therefore plasma caffeine levels were likely 
greatest during the night. In this study, mice were sacrificed at mid-morning, indicating 
extracellular brain adenosine levels were significantly elevated hours after peak plasma 
levels of caffeine have fallen. In a related finding, Conlay et al. (1997) found caffeine 
administration to rats resulted in elevated plasma adenosine levels eight hours later. 
Although it is likely caffeine transiently raises adenosine levels after increasing cellular 
metabolism while increasing vasoconstriction in the brain, this effect should diminish as 
caffeine is metabolized and its antagonism of adenosine receptors removed. The longer 
duration of increased adenosine levels (i.e. eight hours after caffeine administration) thus 
may be a result of increased S-adenosyl-homocysteine (SAH) hydrolysis, resulting in the 
freeing of intracellular adenosine. 
This potential link between caffeine administration and increased SAH hydrolysis 
suggests that caffeine may have an impact on the impaired SAM/SAH cycle in 
Alzheimer’s disease (see Figure 2), which has been shown through in vitro studies to 
affect PS1 and BACE expression (Fuso et al., 2005). Decreases in SAM (S-adenosyl-
methionine) concentrations have been reported in AD patients (Morrison et al., 1996), 
while SAH levels are found to be increased in AD patients (Kennedy et al., 2004). In the 
present study, we found caffeine treatment raised SAM levels by 49% compared to 
untreated Tg mice.  Although this increase was not statistically significant, possibly due 
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to either small group sizes (n=3) or euthanasia at a time well after maximal drinking (e.g., 
caffeine intake) , the data suggest caffeine raises SAM levels, leading to decreased 
expression of PS1 and BACE and subsequent decreased production of Aβ (see Figure 3).  
Proposed Mechanism of Caffeine-Mediated Cognitive Improvement 
 The leading theory in Alzheimer’s research is the amyloid hypothesis, which 
proposes that an increased production of β-amyloid is responsible for a cascade of NFT 
formation, oxidative damage, neuroinflammation, and neurodegeneration/neuronal 
dysfunction.  Supporting this theory, transgenic mice overexpressing a hAPP gene with 
amyloidogenic mutations over-express mutant APP, resulting in production of Aβ and 
ensuing cognitive impairment. In the present study, long-term caffeine treatment reduced 
Aβ and protected the mice from cognitive impairment.  
 A previous study investigating the potential neurprotective effects of caffeine was 
limited to an in vitro investigation that failed to account for caffeine-mediated 
physiological changes aside from the pharmological blockade of adenosine receptors 
(Dall’Igna et al., 2003).  These investigators reported that A2A receptor blockade by 
caffeine in cultured rat cerebellum cells resulted in neuroprotection against β-amyloid 
toxicity. Past literature suggests, however, that A2A receptors are limited to insignificant 
numbers in cerebellum cells (Fredholm et al., 1999; Fisone et al., 2004). It is also known 
that cerebellum cells are not normally subjected to high levels of β-amyloid until possibly 
the very late stages of advanced Alzheimer’s disease. If caffeine-mediated blockade of 
A2A receptors was neuroprotective, then this would also dictate that caffeine must be 
present in the bloodstream at all times. The epidemiological study by Maia and 
Mendonca (2002) reported that a caffeine intake of 199 mg/day (approximately two cups 
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of coffee) reduced the risk of Alzheimer’s disease, indicating that a sustained presence of 
caffeine is not required for caffeine’s protective affects on cognitive function.  In the 
present study, the nature of the long-term caffeine treatment was designed to closely 
mimic the normal consumption of caffeine in a typical caffeine user. With this in mind, 
the in vivo effects of long-term caffeine intake on the cognitive function and pathological 
features of APPsw mice could be examined through the present controlled study, which 
eliminated other potential variables over a protracted longitudinal treatment format. 
 Caffeine is derived from a biosynthetic pathway in tea leaves that begins with the 
precursor S-adenosyl-methionine (SAM) (Koshiishi et al., 2001).  SAM is a major methyl 
donor in the brain and is involved in the methylation status of various genes including 
PS1 and BACE (Fuso et al., 2005). Under normal circumstances, SAM is converted to 
SAH by catechol-O-methyltransferase (COMT) while donating its methyl group and 
SAH is rapidly hydrolyzed to adenosine and homocysteine. When homocysteine is 
present in higher concentrations, such as AD, the equilibrium reaction proceeds in the 
opposite direction and favors the formation of SAH from adenosine and homocysteine. 
Elevations in SAH could potentially block the methylation reaction leading to increased 
expression of PS1 and BACE (Scarpa et al., 2003), and would be evident by decreases in 
extracellular adenosine as it is synthesized into intracellular SAH. 
 Elevated plasma levels of homocysteine are considered a strong independent risk 
factor for AD (Seshadri et al., 2002), and it was recently reported that AD patients over 
the age of 60 consumed significantly less dietary vitamin B6 and folate than controls 
(Mizrahi et al., 2003). Vitamin B6 and folate are both required for the recycling of 
homocysteine back to methionine, and homocysteine accumulates when these compounds 
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are present in insufficient quantities (Fuso et al., 2005). Dietary influences such as these, 
as well as other genetic or physical alterations that might affect homocysteine 
metabolism, result in accumulation of SAH and the subsequent state of hypomethylation 
proposed in the genes implicated in AD (Scarpa et al., 2003). It is therefore relevant to 
address the link between caffeine, SAM, and SAH in Alzheimer’s disease. 
 It is currently unknown how caffeine might raise SAM levels as this is the first 
study to suggest that a caffeine-induced elevation in SAM occurs. It is possible caffeine 
is directly metabolized back to SAM once absorbed into the body, as caffeine is a 
downstream product of SAM biosynthesis in tea leaves. Another proposed theory relies 
on caffeine down-regulating astrocytic metabolism by antagonizing A2A receptors in 
these cells, which contain the majority of COMT present in the brain. The potential 
inactivation of COMT in this manner would lead to a decrease in transformation of SAM 
to SAH, promoting the methylation status of PS1 and BACE. On this note, COMT 
inhibitors have been used to treat depression (a symptom of Alzheimer’s disease) and are 
reported to decrease the L-dopa induced increases in homocysteine that accompany 
Parkinson’s disease patients (Miller et al., 1997). It was also recently found that direct 
activation of COMT stimulates homocysteine synthesis in astrocytes, which in turn 
export homocysteine to neighboring neurons (Huang et al., 2005). A caffeine-mediated 
inhibition of COMT-induced homocysteine synthesis would thus have beneficial 
implications in a variety of diseases in addition to AD. 
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Clinical Implications of Caffeine Administration Study Findings and Potential Future 
Investigations 
 In and of itself, the near-complete protection against cognitive impairment 
granted by the long-term administration of caffeine to APPsw mice warrants further 
studies into the relationship between caffeine and Alzheimer’s disease. Furthermore, the 
substantial decreases in Aβ following caffeine treatment provide evidence that caffeine 
does have a positive effect (perhaps indirectly) on amyloidogenic processing that results 
in behavioral improvements. The proposed link between a caffeine-induced change in the 
SAM/SAH cycle and the effect this relationship potentially has on SAM methylation of 
BACE and PS1 activity would be novel in providing a link between a dietary influence 
and the genetics of Alzheimer’s disease.  In addition to this proposed “indirect” 
mechanism for caffeine affecting amyloidogenic pathways, it is possible that “direct” 
effects of caffeine on neuronal amyloidogenic pathways are also present.  In vitro 
neuronal culture studies could determine if such direct affects are, indeed, part of the 
beneficial mechanisms through which caffeine reduces brain Aβ levels and protects 
cognitive function. 
 The suggested diminishment of PS1 expression following caffeine treatment has 
potentially powerful repercussions. First, decreased PS1 expression following long-term 
caffeine use would result in decreases in the pathological amyloidogenic processing 
found in Alzheimer’s disease as suggested, but this decrease in expression would also not 
result in a complete loss of function of the PS1 gene, sidestepping the potential harmful 
effects that often accompany PS1 inhibitors. Secondly, the 18-day treatment of caffeine 
used in study B of this investigation also resulted in a substantial decrease in Aβ as well, 
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indicating that caffeine administration may serve as an effective treatment against those 
already diagnosed with AD.  Lastly, the use of caffeine is already widely accepted by the 
global community and is cost effective. It has also been established that moderate use of 
caffeine is unaccompanied by harmful side effects as long as caffeine intake is 
maintained on a daily basis.  Thus, it is a safe, naturally-occurring nutraceutic agent that 
could have significant prophylactic and therapeutic value against AD, whether taken 
alone or in combination with other AD therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 117
References 
 
1. Abbracchio MP, Colombo F, Di Luca M, Zaratin P, Cattabeni F. Adenosine 
modulates the dopaminergic function in the nigro-striatal system by interacting with 
striatal dopamine dependent adenylate cyclase. Pharmacol Res Commun 19: 275-
286. 1987. 
 
2. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and 
acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. 
Neuropsychopharmacology 27: 182-93. 2002. 
 
3. Andresen, BT; Gillespie, DG; Mi, Z; Dubey, RK; and Jackson, EK. Role of 
adenosine A1 receptors in modulating extracellular adenosine levels. J Pharmacol 
Exp Ther 291: 76-80. 1999. 
 
4. Angelucci ME, Cesario C, Hiroi RH, Rosalen PL, Da Cunha C. Effects of caffeine 
on learning and memory in rats tested in the Morris water maze. Braz J Med Biol 
Res 35: 1201-8. 2002. 
 
5. Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia 
MF. Multi-metric behavioral comparison of APPsw and P301L models for 
Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in 
forebrain. Brain Res 1012: 29-41. 2004. 
 
6. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, and 
Diamond DM. Progressive, age-related behavioral impairments in transgenic mice 
carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain 
Res 891: 42-53. 2001. 
 
7. Arendash, GW; and King, DL. Intra- and intertask relationships in a behavioral test 
battery given to Tg2576 transgenic mice and controls. Physio Beh 75:  643-652. 
2002. 
 
8. Arnaud, MJ. The pharmacology of caffeine. Prog Drug Res 31: 273-313. 1987. 
 
9. Arnaud, MJ. Metabolism of caffeine and other components of coffee, in Caffeine, 
Coffee and Health. pp 43-95, Raven Press, New York. 1993. 
 
10. Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med 41: 277-88. 1990. 
 
11. Benowitz, NL; Jacob, P; Mayan, H; and Denaro, C. Sympathomimetic effects of 
paraxanthine and caffeine in humans. Clin Pharmacol Ther 58: 684-91. 1995. 
 
 118
12. Benzing, WC; Wujek, JR; Ward, EK; Shaffer, D; Ashe, KH; Younkin, SG; and 
Brunden, KR. Evidence for glial-mediated inflammation in aged APPsw transgenic 
mice. Neurobiol Aging 20: 581-589. 1999. 
 
13. Bertrand CA, Pomper I, Hillman G, Duffy JC, Micheli I. No relation between coffee 
and blood pressure. N Eng J Med 299: 315-6. 1978. 
 
14. Bhattacharya SK, Satyan KS, Chakrabarti A. Anxiogenic action of caffeine: an 
experimental study in rats. J Psychopharmacol 11: 219-24. 1997. 
 
15. Blanchard, J and Sawers, SJ. The absolute bioavailability of caffeine in man. Eur J 
Clin Pharmacol 24: 93-98. 1983a. 
 
16. Blanchard, J and Sawers, SJ. Comparative pharmacokinetics of caffeine in young 
and elderly men. J Pharmacokinet Biopharm 11: 109-26. 1983b. 
 
17. Bonati, M; Latini, R; Tognoni, G, Young, JF; and Garattini, S. Interspecies 
comparison of in vivo caffeine pharmokinetics in man, monkey, rabbit, rat, and 
mouse. Drug Metab Rev 15: 1355-1383. 1984. 
 
18. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland 
NG, Price DL, and Sisodia SS. Accelerated amyloid deposition in the brains of 
transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. 
Neuron 19: 939-945. 1997. 
 
19. Brown SJ, James S, Reddington M, Richardson PJ. Both A1 and A2a purine 
receptors regulate striatal acetylcholine release. J Neurochem 55: 31-8. 1990. 
 
20. Buerger, K; Zinkowski, R; Teipel, SJ; Arai, H; DeBernardis, J; Kerkman, D; 
McCulloch, C; Padberg, F; Faltraco, F; Goernitz, A; Tapiola, T; Rapoport, SI; 
Pirttila, T; Moller, HJ; and Hampel, H. Differentiation of geriatric major depression 
from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231. Am 
J Psychiatry 160: 376-379. 2003. 
 
21. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, 
Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, and Jucker M. 
Neuronal overexpression of mutant amyloid precursor protein results in prominent 
deposition of cerebrovascular amyoid. Proc Natl Acad Sci USA 96: 14088-14093. 
1999. 
 
22. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-
Pierrat C, Staufenbiel M, Sommer B, and Jucker M. Neuron loss in APP transgenic 
mice. Nature 395: 755-56. 1998. 
 
 119
23. Castellano C. Effects of caffeine on discrimination learning, consolidation, and 
learned behavior in mice. Psychopharmacology 48: 255-260. 1976. 
 
24. Chapman, PF; White, GL; Jones, MW; Cooper-Blacketer, D; Marshall, VJ; Irizarry, 
M; Younkin, L; Good, MA; Bliss, TV; Hyman, BT; Younkin, SG; and Hsiao, KK. 
Impaired synaptic plasticity and learning in aged amyloid precursor protein 
transgenic mice. Nat Neurosci 2:271-276. 1999. 
 
25. Chen, G; Chen, K; Knox, J; Inglis, J; Bernard, A; Martin, S; Justice, A; 
McConlogue, L; Games, D; Freedman, S; and Morris, R. A learning deficit related 
to age and β-amyloid plaques in a mouse model of Alzheimer’s disease. Nature 408: 
975-979. 2000. 
 
26. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, 
Castagnoli N Jr, Schwarzschild MA. Neuroprotection by caffeine and A(2A) 
adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21: 
RC143. 2001. 
 
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones 
DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
National Heart, Lung, and Blood Institute; National High Blood Pressure Education 
Program Coordinating Committee. Seventh report of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 42:1206-1252. 2003. 
 
28. Chou TM, Benowitz NL. Caffeine and coffee: effects on health and cardiovascular 
disease. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 109: 173-89. 
1994. 
 
29. Conlay, LA; Conant, JA; deBros, F; and Wurtman, R. Caffeine alters plasma 
adenosine levels. Nature 389: 136. 1997. 
 
30. Dall'Igna OP, Porciuncula LO, Souza DO, Cunha RA, Lara DR. Neuroprotection by 
caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J 
Pharmacol 138: 1207-9. 2003. 
 
31. Dall'Igna OP, Souza DO, Lara DR. Caffeine as a neuroprotective adenosine receptor 
antagonist. Ann Pharmacother 38: 717-8. 2004. 
 
32. Deckert J, Abel F, Kunig G, Hartmann J, Senitz D, Maier H, Ransmayr G, Riederer 
P. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for 
lack of specificity. Neurosci Lett 244: 1-4. 1998. 
 
 120
33. DeToledo-Morrell, L; Stoub, TR; Bulgakova, M; Wilson, RS; Bennett, DA; 
Leurgans, S; Wuu, J; and Turner, DA. MRI-derived entorhinal volume is a good 
predictor of conversion from MCI to AD. Neurobiol Aging 9: 1197-1203. 2004. 
 
34. Dixon AK, Widdowson L, Richardson PJ. Desensitisation of the adenosine A1 
receptor by the A2A receptor in the rat striatum. J Neurochem 69: 315-21. 1997. 
 
35. Dodart, J; Meziane, H; Mathis, C; Ungerer, A; Bales, K; and Paul, S. Behavioral 
disturbances in transgenic mice overexpressing the V717F β-amyloid precursor 
protein. Behav Neurosci 113: 982-990. 1999. 
 
36. Dodart, JC; Mathis, C; Saura, J; Bales, K; Paul, S; and Ungerer, A. 
Neuroanatomical abnormalities in behaviorally characterized APPV717F transgenic 
mice. Neurobiol dis. 7: 71-85. 2000. 
 
37. Dodart, J; Mathis, C; Bales, K; and Paul, S. Does my mouse have Alzheimer’s 
disease? Genes, Brain, and Behavior 1: 142-155. 2002. 
 
38. Dumont M, Strazielle C, Staufenbiel M, Lalonde R. Spatial learning and exploration 
of environmental stimuli in 24-month-old female APP23 transgenic mice with the 
Swedish mutation. Brain Res 1024: 113-21. 2004. 
 
39. Durlach PJ. The effects of a low dose of caffeine on cognitive performance. 
Psychopharmacology 140: 116-9. 1998. 
 
40. Evenden JL, Turpin M, Oliver L, Jennings C. Caffeine and nicotine improve visual 
tracking by rats: a comparison with amphetamine, cocaine and apomorphine. 
Psychopharmacology 110: 169-76. 1993. 
 
41. Feldman, H; Scheltens, P; Scarpini, E; Hermann, N; Mesenbrink, P; Mancione, L; 
Tekin, S; Lane, R; and Ferris, S. Behavioral Symptoms in MCI. Neurology 62: 
1199-1201. 2004. 
 
42. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-
receptor interactions as an integrative mechanism in the basal ganglia. Trends 
Neurosci 20: 482-7. 1997. 
 
43. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ. 
Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-
receptors. Glia 18: 152-60. 1996. 
 
44. Fisone, G; Borgkvist, A; and Usiello, A. Caffeine as a psychomotor stimulant: 
mechanism of action. Cell Mol Life Sci 61: 857-872. 2004. 
 
 121
45. Flagmeyer I, Haas HL, Stevens DR. Adenosine A1 receptor-mediated depression of 
corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro. Brain 
Res 778: 178-85. 1997. 
 
46. Forbes, K; Shanks, M; and Venneri, A. The Evolution of Dysgraphia in AD. Brain 
Research Bull 63: 19-24. 2004. 
 
47. Fratiglioni, L; Paillard-Borg, S; and Winblad, B. An active and socially integrated 
lifestyle in late life might protect against dementia. Lancet Neurol. 6: 343-53. 2004. 
 
48. Frautschy, SA; Yang, F; Irrizarry, M; Hyman, B; Saido, TC; Hsaio, K; and Cole, 
GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J 
Pathol 152: 307-317. 1998. 
 
49. Fredholm, BB; Abbracchio, MP; Burnstock, G; Daly, JW; Harden, TK; Jacobsen, 
KA; et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 46: 
143-156. 1994. 
 
50. Fredholm, B; Battig, K; Holmen, J; Nehlig, A; and Zvartau, E. Actions of caffeine 
in the brain with special reference to factors that contribute to its widespread use. 
Pharmacol Rev 51: 83-133. 1999. 
 
51. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, and Scarpa S. S-
adenosylmethionine/homocysteine cycle alterations modify DNA methylation status 
with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol 
Cell Neurosci 28: 195-204. 2005. 
 
52. Games, D; Adams, D; Alessandrini, R; Barbour, R; Berthelette, P; Blackwell, C; 
Carr, T; Clemens, J; Donaldson, T; Gillespie, F; Guido, T; Hagopian, S; Johnson-
Wood, K; Khan, K; Lee, M; Leibowitz, P; Lieberburg, I; Little, S; Masliah, E; 
McConlogue, L; Montoya-Zavala, M; Mucke, L; Paganini, L; Penniman, E; Power, 
M; Schenk, D; Seubert, P; Snyder, B; Soriano, F; Tan, H; Vitale, J; Wadsworth, S; 
Wolozin, B; and Zhao, J. Alzheimer-type neuropathology in transgenic mice 
overexpressing V717F β-amyloid precursor protein. Nature 373: 523-7. 1995. 
 
53. Gaskell, P; and Vance, J. Alzheimer’s Disease Genes and Genetic Testing in clinical 
practice. JAAPA 3: 25-31. 2004. 
 
54. Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C. Caffeine reverses the memory 
disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 55: 101-6. 
2001. 
 
55. Goncalves ML, Cunha RA, Ribeiro JA. Adenosine A2A receptors facilitate 45Ca2+ 
uptake through class A calcium channels in rat hippocampal CA3 but not CA1 
synaptosomes. Neurosci Lett 238: 73-7. 1997. 
 122
 
56. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor 
K, Melachrino J, O'Callaghan JP, and Morgan D. Time course of the development 
of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. 
Experimental Neuro 173: 183-195. 2002. 
 
57. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, 
Woodson PP. Low-dose caffeine physical dependence in humans. J Pharmacol Exp 
Ther 255: 1123-32. 1990. 
 
58. Gu, JG; Foga, IO; Parkinson, FE; and Geiger, JD. Involvement of bidirectional 
adenosine transporters in the release of L-{H3}adenosine from rat brain 
synaptosomal preparations. J Neurochem 64: 2105-2110. 1995. 
 
59. Halldner L, Aden U, Dahlberg V, Johansson B, Ledent C, Fredholm BB. The 
adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of 
caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A 
receptors. Neuropharmacology 46: 1008-17. 2004. 
 
60. Hameleers PA, Van Boxtel MP, Hogervorst E, Riedel WJ, Houx PJ, Buntinx F, 
Jolles J. Habitual caffeine consumption and its relation to memory, attention, 
planning capacity and psychomotor performance across multiple age groups. Hum 
Psychopharmacol 15: 573-581. 2000. 
 
61. Hardy, J; and Selkoe, D. The Amyloid Hypothesis of Alzheimer’s disease: Progress 
and Problems on the Road to Therapeutics. Science 297: 353-356. 2002 
 
62. Hebert, L; Scherr, P; Bienias, J; Bennett, D; and Evans, D. Alzheimer disease in the 
US Population. Arch Neurol 60: 1119-1122. 2003. 
 
63. Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, Jaber M, 
Studler JM, Girault JA. Galpha(olf) levels are regulated by receptor usage and 
control dopamine and adenosine action in the striatum. J Neurosci 21: 4390-9. 2001. 
 
64. Higashi T, Sone Y, Ogawa K, Kitamura YT, Saiki K, Sagawa S, Yanagida T, 
Seiyama A. Changes in regional cerebral blood volume in frontal cortex during 
mental work with and without caffeine intake: functional monitoring using near-
infrared spectroscopy. J Biomed Opt 9: 788-93. 2004. 
 
65. Hiruma, H; Katakura, T; Takahashi, S; Ichikawa, T; and Kawakami, T. Glutamate 
and amyloid β-Protein rapidly inhibit fast axonal transport in cultured rat 
hippocampal neurons by different mechanisms. J Neurosci 26: 8967-77. 2003. 
 
66. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, 
Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, 
 123
Eckman C, Younkin S, Hsiao K, and Duff K. Accelerated Alzheimer-type 
phenotype in transgenic mice carrying both mutant amyloid precursor protein and 
presenilin 1 transgenes. Nat Med 4: 97-100. 1998. 
 
67. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, and Morgan D. Behavioral 
changes in transgenic mice expressing both amyloid precursor protein and 
presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29: 
177-85. 1999. 
  
68. Holmes, C; Wilkinson, D; Dean, C; Vethanayagam, S; Olivieri, S; Langley, A; 
Pandita- Gunawardena, HD; Hogg, F; Clare, C; and Damms, J. The efficacy of 
donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease. 
Neurology 63: 214-219. 2004.  
 
69. Hsiao, K; Chapman, P; Nilsen, S; Eckman, C; Harigaya, Y; Younkin, S; Yang, F; 
and Cole, G. Correlative memory deficits, Aβ elevation, and amyloid plaques in 
transgenic mice. Science 274: 99-102. 1996. 
 
70. Huang G, Dragan M, Freeman D, Wilson JX. Activation of catechol-O-
methyltransferase in astrocytes stimulates homocysteine synthesis and export to 
neurons. Glia 51:47-55. 2005. 
 
71. Ishii, K; Sasaki, M; Yamaji, S; Sakamoto, S; Kitagaki, H; and Mori, E. Relatively 
preserved hippocampal glucose metabolism in mild Alzheimer’s disease. Dement 
Geriatr Cogn Disord. 6: 317-322. 1998. 
 
72. Irizarry, M; Soriano, F; McNamara, M; Page, K; Schenk, D; Games, D; and Hyman, 
B. Aβ deposition is associated with neuropil changes, but not with overt neuronal 
loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J 
Neurosci 17: 7053- 7059. 1997. 
 
73. Izquierdo JA, Costas SM, Justel EA, Rabiller G. Effect of caffeine on the memory 
of the mouse. Psychopharmacology 61: 29-30. 1979. 
 
74. Jack, CR; Petersen, RC; Xu, YC; Waring, SC; O’Brien, PC; Tangalos, EG; Smith, 
GE; Ivnik, RJ; and Kokmen, E. Medial temporal atrophy on MRI in normal aging 
and very mild Alzheimer’s disease. Neurology 49: 786-794. 1997. 
 
75. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: 
differences with acute versus chronic treatment. Trends Pharmacol Sci 17: 108-13. 
1996. 
 
76. James JE. Acute and chronic effects of caffeine on performance, mood, headache, 
and sleep. Neuropsychobiology 38: 32-41. 1998. 
 
 124
77. Jarvis MJ. Does caffeine intake enhance absolute levels of cognitive performance? 
Psychopharmacology 110: 45-52. 1993. 
 
78. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, and Arendash GW. Lifelong 
immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice 
against cognitive impairment throughout aging. Neuroscience 130: 667-684. 2005. 
 
79. Johansson B, Ahlberg S, van der Ploeg I, Brene S, Lindefors N, Persson H, 
Fredholm BB. Effect of long term caffeine treatment on A1 and A2 adenosine 
receptor binding and on mRNA levels in rat brain. Naunyn-Schmiedeburg’s Arch 
Pharmacol 347: 407-414. 1993. 
 
80. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, 
Brune D, Sisodia SS, Staufenbiel M, Emmerling M, and Roher AE. APP transgenic 
mice Tg2576 accumulate Abeta peptides that are distinct from the chemically 
modified and insoluble peptides deposited in Alzheimer's disease senile plaques. 
Biochemistry 41: 922-928. 2002. 
 
81. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-
mediated axonal transport of a membrane compartment containing beta-secretase 
and presenilin-1 requires APP. Nature 414: 643-8. 2001. 
 
82. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, 
Shader RI. Dose-dependent pharmacokinetics and psychomotor effects of caffeine 
in humans. J Clin Pharmacol 37: 693-703. 1997. 
 
83. Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z, 
Pezzola A, Reggio R, Muller CE, Fuxe K, Goldberg SR, Popoli P, Ferre S. 
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine 
after its acute and chronic administration. Neuropsychopharmacology 28: 1281-
1291. 2003. 
 
84. Kawarabayashi, T; Younkin, LH; Saido, TC; Shoji, M; Ashe, KH; and Younkin SG. 
Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 
transgenic mouse model of Alzheimer’s disease. J Neurosci 21: 372-381. 2001. 
 
85. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, 
Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, 
Staufenbiel M, and Sommer B. Progressive age-related impairment of cognitive 
behavior in APP23 transgenic mice. Neurobiol Aging 24: 365-78. 2003. 
 
86. Kennedy, BP; Bottiglieri, T; Arning, E; Ziegler, MG; Hansen, LA; and Masliah, E. 
Elevated S-adenosylhomocysteine in Alzheimer brain: influence on 
methyltransferases and cognitive function. J Neural Transm 111: 547-567. 2004. 
 
 125
87. King, DL; Arendash, GW; Crawford, F; Sterk, T; Menendez, J; and Mullan, MJ. 
Progressive and gender-dependent cognitive impairment in the APPsw transgenic 
mouse model of Alzheimer’s disease. Behavior Brain Res 103: 145-162. 1999. 
 
88. King, DL; and Arendash, GW. Behavioral characterization of the Tg2576 transgenic 
mouse model of Alzheimer’s disease through 19 months. Physio Beh 75: 627-642. 
2002. 
 
89. Kittner, B; Rossner, M; and Rother, M. Clinical trials in dementia with 
propentofylline. Ann NY Acad Sci 826: 307-16. 1997. 
 
90. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, 
Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, 
Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, and Langstrom B. 
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann 
Neurol. 55: 306-19. 2004. 
 
91. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures 
J, and Higgins LS. Specific spatial learning deficits become severe with age in beta -
amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits 
but do not form plaques. Proc Natl Sci USA 98: 14675-14680. 2001. 
 
92. Koshiishi C, Kato A, Yama S, Crozier A, Ashihara H. A new caffeine biosynthetic 
pathway in tea leaves: utilisation of adenosine released from the S-adenosyl-L-
methionine cycle. FEBS Lett 499: 50-4. 2001. 
 
93. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, 
Haughey N, Lee J, Evans M, Mattson MP. Folic acid deficiency and homocysteine 
impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity 
in experimental models of Alzheimer's disease. J Neurosci 22: 1752-62. 2002. 
 
94. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, 
Abramowski D, Sturchler-Pierrat C, Staufenbiel M, and Roher AE. Comparative 
analysis of amyloid-beta chemical structure and amyloid plaque morphology of 
transgenic mouse and Alzheimer's disease brains. J Biol Chem 276: 12991-12998. 
2001. 
 
95. Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C. Spatial 
learning, exploration, anxiety, and motor coordination in female APP23 transgenic 
mice with the Swedish mutation. Brain Res 956: 36-44. 2002. 
 
96. Larson, J; Lynch, G; Games, D; and Seubert, P. Alterations in synaptic transmission 
and long-term potentiation in hippocampal slices from young and aged PDAPP 
mice. Brain Research 840: 23-35. 1999. 
 
 126
97. Leighty RE, Nilsson LN, Potter H, Costa DA, Low MA, Bales KR, Paul SM, 
Arendash GW. Use of multimetric statistical analysis to characterize and 
discriminate between the performance of four Alzheimer's transgenic mouse lines 
differing in Abeta deposition. Behav Brain Res 153: 107-21. 2004. 
 
98. Linden J. Molecular approach to adenosine receptors: receptor-mediated 
mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-87. 2001. 
 
99. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, 
Mautino J, Vigo FS, Sommer B, and Yankner BA. Amyloid beta interacts with the 
amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat 
Neurosci 3: 460-464. 2000. 
 
100. MacDonald RL, Skerritt JH, and Werz MA. Adenosine agonists reduce voltage-
dependent calcium conductance of mouse sensory neurones in cell culture. J Physio 
370: 75-90. 1986.  
 
101. Maia, L, and de Mendonca, A. Does caffeine intake protect from Alzheimer’s 
disease? Euro J Neuro 9: 377-382. 2002. 
 
102. Masliah, E; Sisk, A; Mallory, M; Mucke, L; Schenk, D; and Games, D. Comparison 
of neurodegenerative pathology in transgenic mice overexpressing V717F β-
amyloid precursor protein and Alzheimer’s disease. J Neurosci 16: 5795- 5811. 
1996. 
 
103. Mathis, CA; Wang, Y; and Klunk, WE. Imaging beta-amyloid plaques and 
neurofibrillary tangles in the aging human brain. Curr Pharm Des. 13:1469-92. 
2004. 
 
104. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, 
Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. 
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's 
disease. Am J Pathol 158: 1345-54. 2001. 
 
105. Mattson, M; Cheng, B; Davis, D; Bryant, K; Lieberburg, I; and Rydel, R. 
β−Amyloid peptides destabilize calcium homeostasis and render human cortical 
neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389. 1992. 
 
106. McPherson, PS; Kim, YK; Valdivia, H; Knudson, CM; Takekura, H; Franzini-
Armstrong C; et al. The brain ryanodine receptor: a caffeine-sensitive calcium 
release channel. Neuron 7: 17-25. 1991. 
 
107. Meyer L, Caston J. Stress alters caffeine action on investigatory behaviour and 
behavioural inhibition in the mouse. Behavioral Brain Research 149: 87-93. 2004. 
 
 127
108. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. 
Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on 
sulfur amino acid metabolites in rats. Clin Neuropharmacol 20: 55-66. 1997. 
 
109. Miner, SE; Evrovski, J; and Cole, D. Clinical chemistry and molecular biology of 
homocysteine metabolism: An update. Clin Biochem 30: 189-201. 1997. 
 
110. Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, and 
Petot GJ. Plasma total homocysteine levels, dietary vitamin B6 and folate intake in 
AD and healthy aging. J Nutr Health Aging 7: 160-165. 2003. 
 
111. Molinengo L, Scordo I, Pastorello B. Action of caffeine, L-PIA and their 
combination on memory retention in the rat. Life Sci 54: 1247-50. 1994. 
 
112. Moran, M; Walsh, C; and Lynch, A. Syndromes of behavioral and psychological 
symptoms in mild AD. Int J Geriatr Psychiatry 19: 359-364. 2004 
 
113. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, 
Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, 
Arendash GW. A beta peptide vaccination prevents memory loss in an animal 
model of Alzheimer's disease. Nature 408: 982-5. 2000. 
 
114. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2: 425-428. 
2003. 
 
115. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely 
decreased in Alzheimer's disease. J Neurochem 67: 1328-31. 1996. 
 
116. Mullan, M; Crawford, F; Axelman, K; Houlden, H; Lilius, L; Winblad, B; and 
Lannfelt, L. A pathogenic mutation for probable Alzheimer’s disease in the APP 
Gene at the N-terminus of beta-amyloid. Nat Genet 1: 345-347. 1992. 
 
117. Myers MG. Effect of caffeine on blood pressure beyond the laboratory. 
Hypertension 43: 724-5. 2004. 
 
118. Nehlig A, Boyet S. Dose-response study of caffeine effects on cerebral functional 
activity with a specific focus on dependence. Brain Res 858: 71-7. 2000. 
 
119. Nestor, P; Scheltens, P; and Hodges, J. Advances in the early detection of 
Alzheimer’s disease. Nature Reviews Neuroscience 5: S34-S41. 2004. 
 
120. Nilsson, LN; Arendash, GW; Leighty, RE; Costa, DA; Low, MA; Garcia, MF; 
Cracciolo, JR; Rojiani, A; Wu, X; Bales, KR; Paul, SM; and Potter, H. Cognitive 
Impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid 
formation. Neurobiol Aging 25:1153-1167. 2004. 
 128
 
121. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in 
downregulation of inflammation and protection from tissue damage. Nature 414: 
916-20. 2001. 
 
122. Okada M, Mizuno K, Kaneko S. Adenosine A1 and A2 receptors modulate 
extracellular dopamine levels in rat striatum. Neurosci Lett 212: 53-56. 1996. 
 
123. Ongini, E. and Schubert, P. Neuroprotection induced by stimulating A1 or blocking 
A2A adenosine receptors: an apparent paradox. Drug Develop Res 45: 387-393. 
1998. 
 
124. O'Regan MH, Simpson RE, Perkins LM, Phillis JW. The selective A2 adenosine 
receptor agonist CGS 21680 enhances excitatory transmitter amino acid release 
from the ischemic rat cerebral cortex. Neurosci Lett 138: 169-72. 1992. 
 
125. Pappolla, MA; Chyan, YJ; Omar, RA.; Hsiao, K; Perry, G; Smith, MA; and Bozner, 
P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a 
transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for 
testing antioxidant therapies in vivo. Am J Pathol 152: 871-7. 1998. 
 
126. Paris D, Town T, Parker TA, Tan J, Humphrey J, Crawford F, and Mullan M. 
Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory 
response in microglia by a cGMP-dependent mechanism. Exp Neurol 157: 211-21. 
1999. 
 
127. Patat A, Rosenzweig P, Enslen M, Trocherie S, Miget N, Bozon MC, Allain H, 
Gandon JM. Effects of a new slow release formulation of caffeine on EEG, 
psychomotor and cognitive functions in sleep-deprived subjects. Hum 
Psychopharmacol 15: 153-70. 2000. 
 
128. Petersen, R; Doody, R; Kurz, A, Mohs, R; Morris, J; Rabins, P; Ritchie, K; Rossor, 
M; Thal, L; and Winblad, B. Current concepts in MCI. Arch Neurol 58: 1985-1992. 
2001. 
 
129. Polidori, MC. Oxidative stress and risk factors for Alzheimer’s disease: clues to 
prevention and therapy. J Alzheimer’s Dis. 2: 185-91. 2004. 
 
130. Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular 
platform spatial memory task for mice: use in detecting cognitive impairment in the 
APP(SW) transgenic mouse model for Alzheimer's disease. J Neurosci Methods  87: 
87-95. 1999. 
 
 129
131. Popoli P, Betto P, Reggio R, Ricciarello G. Adenosine A2A receptor stimulation 
enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287: 215-
217. 1995. 
 
132. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pezzola A, Scarchilli L, 
Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M. Blockade of 
striatal adenosine A2A receptor reduces, through a presynaptic mechanism, 
quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective 
interventions in neurodegenerative diseases of the striatum. J Neurosci 22: 1967-75. 
2002. 
 
133. Potter, H; Wefes, IM; Nilsson, LN. The inflammation-induced pathological 
chaperones ACT and apo-e are necessary catalysts of Alzheimer amyloid formation. 
Neurobio Aging 22: 923-30. 2001. 
 
134. Quadri, P; Fragiacomo, C; Pezzati, R; Zanda, E; Forloni, G; Tettamanti, M; and 
Lucca, U. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, 
Alzheimer’s disease, and vascular dementia. Am J Clin Nutr. 80: 114-22. 2004. 
 
135. Quadros A, Patel N, Crescentini R, Crawford F, Paris D, and Mullan M. Increased 
TNFalpha production and Cox-2 activity in organotypic brain slice cultures from 
APPsw transgenic mice. Neurosci Lett 353: 66-68. 2003. 
 
136. Rainnie DG, Grunze HC, McCarley RW, Greene RW. Adenosine inhibition of 
mesopontine cholinergic neurons: implications for EEG arousal. Science 263: 689-
92. 1994. 
 
137. Ribeiro, JA; Sebastiao, AM; and de Mendonca, A. Adenosine receptors in the 
nervous system: pathophysiological implications. Prog Neurobiol 68: 377-392. 
2003. 
 
138. Rieg T, Steigele H, Schnermann J, Richter K, Osswald H, Vallon V. Requirement of 
intact adenosine A1 receptors for the diuretic and natriuretic action of the 
methylxanthines theophylline and caffeine. J Pharmacol Exp Ther [Epub ahead of 
print]: 2004. 
 
139. Ringheim GE. Glial modulating and neurotrophic properties of propentofylline and 
its application to Alzheimer's disease and vascular dementia. Ann NY Acad Sci 903: 
529-34. 2000. 
 
140. Rivkees SA, Zhao Z, Porter G, and Turner C. Influences of adenosine on the fetus 
and newborn. Mol Genet Metab 74: 160-171. 2001. 
 
141. Robertson D, Hollister AS, Kincaid D, Workman R, Goldberg MR, Tung CS, Smith 
B. Caffeine and hypertension. Am J Med 77: 54-60. 1984. 
 130
 
142. Ross, GW; Abbott, RD; Petrovitch, H; Morens, DM; Grandinetti, A; Tung, KH; 
Tanner, CM; Masaki, KH; Blanchette, PL; Curb, JD; Popper, JD; and White, LR. 
Association of coffee and caffeine intake with the risk of Parkinson’s disease. JAMA 
20: 2674-9. 2000. 
 
143. Rudolphi KA, Keil M, Hinze HJ. Effect of theophylline on ischemically induced 
hippocampal damage in Mongolian gerbils: a behavioral and histopathological 
study. J Cereb Blood Flow Metab 7: 74-81. 1987. 
 
144. Rudolphi KA, Keil M, Fastbom J, Fredholm BB. Ischaemic damage in gerbil 
hippocampus is reduced following upregulation of adenosine (A1) receptors by 
caffeine treatment. Neurosci Lett 103: 275-280. 1989. 
 
145. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, 
Nixon RA, Gruen RJ, Wisniewski T. Amyloid-beta deposition is associated with 
decreased hippocampal glucose metabolism and spatial memory impairment in 
APP/PS1 mice. J Neuropathol Exp Neurol 63: 418-28.2004. 
 
146. Sansone M, Battaglia M, Castellano C. Effect of caffeine and nicotine on avoidance 
learning in mice: lack of interaction. J Pharm Pharmacol 46: 765-767. 1994. 
 
147. Schenk, D; Masliah, E; Lee, M; Johnson-Wood, K; Seubert, P; and Games, D. The 
PDAPP transgenic mouse as an animal model for Aβ-induced amyloidosis and 
neuropathology. Alzheimer’s Disease Rev 2: 20-27. 1997. 
 
148. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine 
A2 receptor mRNA in the human brain. Neursci Lett 130: 177-81. 1991. 
 
149. Schmitt JA, Hogervorst E, Vuurman EF, Jolles J, Riedel WJ. Memory functions and 
focussed attention in middle-aged and elderly subjects are unaffected by a low, 
acute dose of caffeine. J Nutr Health Aging 7: 301-3. 2003. 
 
150. Schubert, P; Morino, T; Miyazaki, H; Ogata, T; Nakamura, Y; Marchini, C; and 
Ferroni, S. Cascading Glia Reactions: A common pathomechanism and its 
differentiated control by cyclic nucleotide signaling. Ann NY Acad Sci 903: 24-33. 
2000. 
 
151. Schwab, C; Hosokawa, M; and McGeer, PL. Transgenic mice overexpressing 
amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurology 
188: 52-64. 2004. 
 
152. Seabrook, G; and Rosahl, T. Transgenic animals relevant to Alzheimer’s disease.  
Neuropharm 38:1-17. 1999. 
 
 131
153. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on 
the nervous system. Prog Neurobiol 48: 167-89. 1996. 
 
154. Selkoe, D. Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiological 
Reviews 81: 741-766. 2001. 
 
155. Selley, ML. Increased homocysteine and decreased adenosine formation in 
Alzheimer’s disease. Neurol Res 26: 554-7. 2004. 
 
156. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson 
PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's 
disease. New Engl J Med 346: 476-483. 
 
157. Shi D, Nikodijevic O, Jacobson KA, Daly JW. Chronic caffeine alters the density of 
adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium 
channels in mouse brain. Cell Mol Neurobiol 13: 247-261. 1993. 
 
158. Shi J, Benowitz NL, Denaro CP, Sheiner LB. Pharmacokinetic-pharmacodynamic 
modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 53: 6-14. 
1993b. 
 
159. Shi D, Daly JW. Chronic effects of xanthines on levels of central receptors in mice. 
Cell Mol Neurobiol 19: 719-732. 1999. 
 
160. Silva RH, Frussa-Filho R. The plus-maze discriminative avoidance task: a new 
model to study memory-anxiety interactions. Effects of chlordiazepoxide and 
caffeine. J Neurosci Methods 102: 117-125. 2000. 
 
161. Sobow, T; Flirski, M; and Liberski, PP. Amyoid-beta and tau proteins as 
biochemical markers of Alzheimer’s disease. Acta Neurobiol Exp 64: 53-70. 2004. 
 
162. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher 
S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker 
M, Probst A, Staufenbiel M, and Sommer B. Two amyloid precursor protein 
transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad 
Sci USA 94: 13287-92. 1997. 
 
163. Sullivan GW. Adenosine A2A receptor agonists as anti-inflammatory agents. Curr 
Opin Investig Drugs 4: 1313-9. 2003. 
 
164. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry 
and function of striatal adenosine A2A receptors. Prog Neurobiol 59: 355-96. 1999. 
 
165. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann 
DM, Hyman BT, and Iwatsubo T. Age-related amyloid beta deposition in transgenic 
 132
mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor 
protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 
157: 331-339. 2000. 
 
166. Tanaka, Y; Sakurai, M; Goto, M; and Hayashi, S. Effect of xanthine derivatives on 
hippocampal long-term potentiation. Brain Res 522: 63-68. 1990. 
 
167. Tanaka, H; Nakazawa, K; Arima, M; and Iwasaki, S. Caffeine and its 
dimethylxanthines and fetal cerebral development in rat. Brain Dev 6: 355-361. 
1984. 
 
168. Tandon, A; and Fraser, P. The presenilins. Genome Biol 3: 3014-3020. 2002. 
 
169. Tariot. PN; Farlow, MR; Grossberg, GT; Graham, SM; McDonald, S; and Gergel, I. 
Memantine treatment in patients with moderate to severe Alzheimer’s disease 
already receiving donepezil: a randomized controlled trial. JAMA 291: 317-24. 
2004. 
 
170. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive 
age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 
55: 801-14. 2004. 
 
171. Trussell LO, and Jackson MB. Adenosine-activated potassium conductance in 
cultured striatal neurons. Proc Natl Acad Sci 82: 4857-61. 1985. 
 
172. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren 
K, Power C. A1 adenosine receptor upregulation and activation attenuates 
neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 
24: 1521-1529. 2004. 
 
173. Ulas J, Brunner LC, Nguyen L, and Cotman CW. Reduced density of adenosine A1 
receptors and preserved coupling of adenosine A1 receptors to G proteins in 
Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 52: 
843-54. 1993. 
 
174. van Boxtel MP, Schmitt JA, Bosma H, Jolles J. The effects of habitual caffeine use 
on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 75: 
921-7. 2003. 
 
175. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn 
PP. Age-dependent cognitive decline in the APP23 model precedes amyloid 
deposition. Eur J Neurosci 17: 388-96. 2003. 
 
176. Vernikos-Danellis, J and Harris III, CG. The effect of in vitro and in vivo caffeine, 
theophylline, and hydrocortisone on the phosphodiesterase activity of the pituitary, 
median eminence, heart, and cerebral cortex. Proc Soc Exp Biol Med 128: 1016-
1021. 1968. 
 
177. Veurink, G; Fuller, S; Atwood, C; and Martins, R. Genetics, lifestyle, and the roles 
of amyloid β and oxidative stress in Alzheimer’s disease. Ann Human Biol 30: 639-
667. 2003. 
 
178. Vinters, H. V. Stroke 18: 311 324. 1987. 
 
179. Von Lubitz DK, Paul IA, Bartus RT, Jacobson KA. Effects of chronic 
administration of adenosine A1 receptor agonist and antagonist on spatial learning 
and memory. Eur J Pharmacol 249: 271-80. 1993. 
 
180. Wahlund, L; and Blennow, K. Cerebrospinal fluid biomarkers for disease stage and 
intensity in cognitively impaired patients. Neurosci Lett 339: 99-102. 2003. 
 
181. Wallman-Johansson, A; and Fredholm, BB. Release of adenosine and other purines 
from hippocampal slices stimulated electrically or by hypoxia/hypoglycemia. Effect 
of chlormethiazole. Life Sci 55: 721-8. 1994. 
 
182. Westerman, MA; Cooper-Blacketer, D; Mariash, A; Kotilinek, L; Kawarabayashi, 
T; Younkin, LH; Carlson, GA; Younkin, SG; and Ashe, KH. The relationship 
between Aβ and memory in the Tg2576 mouse model of Alzheimer’s disease. J 
Neurosci 22: 1858-1867. 2002. 
 
183. Xu, Y; Jack, CR; O’Brien, PC; Kokmen, E; Smith, GE; Ivnik, RJ; Boeve, BF; 
Tangalos, RG; and Petersen, RC. Usefulness of MRI measures of entorhinal cortex 
versus hippocampus in AD. Neurology 54: 1760-1767. 2000. 
 
184. Yeomans MR, Ripley T, Davies LH, Rusted JM, Rogers PJ. Effects of caffeine on 
performance and mood depend on the level of caffeine abstinence. 
Psychopharmacology 164: 241-9. 2002. 
 
185. Zekanowski, C; Religa, D; Graff, C; Filipek, S; and Kuznicki, J. Genetic aspects of 
Alzheimer’s disease. Acta Neurobiol Exp 64: 19-31. 2004 
 
186. Zimmermann, H; and Braun, N. Ecto-nucleotides-molecular structures, catalytic 
properties, and functional roles in the nervous system. Prog Brain Res 120: 371-
385. 1999. 
 
 
 133
